<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Psychopharmacology (Berl)</journal-id><journal-id journal-id-type="iso-abbrev">Psychopharmacology (Berl.)</journal-id><journal-title-group><journal-title>Psychopharmacology</journal-title></journal-title-group><issn pub-type="ppub">0033-3158</issn><issn pub-type="epub">1432-2072</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28551715</article-id><article-id pub-id-type="pmc">5813072</article-id><article-id pub-id-type="publisher-id">4650</article-id><article-id pub-id-type="doi">10.1007/s00213-017-4650-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group></article-categories><title-group><article-title>Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dolder</surname><given-names>Patrick C.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>M&#x000fc;ller</surname><given-names>Felix</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Schmid</surname><given-names>Yasmin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Borgwardt</surname><given-names>Stefan J.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Liechti</surname><given-names>Matthias E.</given-names></name><address><phone>+41 61 328 68 68</phone><email>matthias.liechti@usb.ch</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.410567.1</institution-id><institution>Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, Department of Clinical Research, </institution><institution>University Hospital Basel and University of Basel, </institution></institution-wrap>Schanzenstrasse 55, CH-4056 Basel, Switzerland </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 0642</institution-id><institution-id institution-id-type="GRID">grid.6612.3</institution-id><institution>Department of Psychiatry (UPK), </institution><institution>University of Basel, </institution></institution-wrap>Basel, Switzerland </aff></contrib-group><pub-date pub-type="epub"><day>27</day><month>5</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>27</day><month>5</month><year>2017</year></pub-date><pub-date pub-type="ppub"><year>2018</year></pub-date><volume>235</volume><issue>2</issue><fpage>467</fpage><lpage>479</lpage><history><date date-type="received"><day>21</day><month>2</month><year>2017</year></date><date date-type="accepted"><day>9</day><month>5</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><sec><title>Rationale</title><p id="Par1">3,4-Methylenedioxymethamphetamine (MDMA) is used recreationally and investigated as an adjunct to psychotherapy. Methylphenidate and modafinil are psychostimulants that are used to treat attention-deficit/hyperactivity disorder and narcolepsy, respectively, but they are also misused as cognitive enhancers. Little is known about differences in the acute effects of equally cardiostimulant doses of these stimulant-type substances compared directly within the same subjects.</p></sec><sec><title>Methods</title><p id="Par2">We investigated the acute autonomic, subjective, endocrine, and emotional effects of single doses of MDMA (125&#x000a0;mg), methylphenidate (60&#x000a0;mg), modafinil (600&#x000a0;mg), and placebo in a double-blind, cross-over study in 24 healthy participants. Acute drug effects were tested using psychometric scales, the Facial Emotion Recognition Task (FERT), and the Sexual Arousal and Desire Inventory (SADI).</p></sec><sec><title>Results</title><p id="Par3">All active drugs produced comparable hemodynamic and adverse effects. MDMA produced greater increases in pupil dilation, subjective good drug effects, drug liking, happiness, trust, well-being, and alterations in consciousness than methylphenidate or modafinil. Only MDMA reduced subjective anxiety and impaired fear recognition and led to misclassifications of emotions as happy on the FERT. On the SADI, only MDMA produced sexual arousal-like effects. Only MDMA produced marked increases in cortisol, prolactin, and oxytocin. In contrast to MDMA, methylphenidate increased subjective anxiety, and methylphenidate and modafinil increased misclassifications of emotions as angry on the FERT. Modafinil had no significant subjective drug effects but significant sympathomimetic and adverse effects.</p></sec><sec><title>Conclusions</title><p id="Par4">MDMA induced subjective, emotional, sexual, and endocrine effects that were clearly distinct from those of methylphenidate and modafinil at the doses used.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1007/s00213-017-4650-5) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>MDMA</kwd><kwd>Methylphenidate</kwd><kwd>Modafinil</kwd><kwd>Emotion recognition</kwd><kwd>Sexual arousal</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008375</institution-id><institution>Universit&#x000e4;t Basel</institution></institution-wrap></funding-source><award-id>no</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001711</institution-id><institution>Schweizerischer Nationalfonds zur F&#x000f6;rderung der Wissenschaftlichen Forschung</institution></institution-wrap></funding-source><award-id>320030_170249</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag GmbH Germany, part of Springer Nature 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) is used recreationally and investigated as an adjunct to psychotherapy for patients with posttraumatic stress disorder (Mithoefer et al. <xref ref-type="bibr" rid="CR46">2010</xref>; Oehen et al. <xref ref-type="bibr" rid="CR49">2013</xref>). Methylphenidate and modafinil are stimulants that are used to treat attention-deficit/hyperactivity disorder and narcolepsy, respectively, but also misused as cognitive enhancers (Liakoni et al. <xref ref-type="bibr" rid="CR36">2015</xref>; Maier et al. <xref ref-type="bibr" rid="CR41">2015</xref>; Maier et al. <xref ref-type="bibr" rid="CR40">2013</xref>; Repantis et al. <xref ref-type="bibr" rid="CR57">2010</xref>). The neurotransmitter interaction profile of MDMA clearly differs from classic psychostimulants (Liechti <xref ref-type="bibr" rid="CR37">2015</xref>). MDMA releases serotonin and oxytocin (Francis et al. <xref ref-type="bibr" rid="CR12">2016</xref>; Hysek et al. <xref ref-type="bibr" rid="CR24">2012c</xref>; Kirkpatrick et al. <xref ref-type="bibr" rid="CR32">2014b</xref>; Simmler et al. <xref ref-type="bibr" rid="CR70">2013</xref>), in contrast to psychostimulant amphetamines (Liechti <xref ref-type="bibr" rid="CR37">2015</xref>; Simmler et al. <xref ref-type="bibr" rid="CR70">2013</xref>) and related substances, such as methylphenidate and modafinil, that enhance dopaminergic and noradrenergic neurotransmission without affecting serotonin or oxytocin (Hannestad et al. <xref ref-type="bibr" rid="CR16">2010</xref>; Madras et al. <xref ref-type="bibr" rid="CR39">2006</xref>; Qu et al. <xref ref-type="bibr" rid="CR53">2008</xref>; Schmeichel and Berridge <xref ref-type="bibr" rid="CR61">2013</xref>; Schmid et al. <xref ref-type="bibr" rid="CR62">2014</xref>; Simmler et al. <xref ref-type="bibr" rid="CR71">2014</xref>; Zolkowska et al. <xref ref-type="bibr" rid="CR91">2009</xref>). The main goal of the present study was to characterize and compare the effects of MDMA with the stimulant-type substances methylphenidate and modafinil at single relatively high doses matched for their cardiostimulant properties (comparable rate-pressure products; Hysek et al. <xref ref-type="bibr" rid="CR26">2014b</xref>; Jasinski <xref ref-type="bibr" rid="CR28">2000</xref>).</p><p id="Par6">The acute effects of MDMA have been extensively studied in healthy subjects (Dumont and Verkes <xref ref-type="bibr" rid="CR8">2006</xref>; Vizeli and Liechti <xref ref-type="bibr" rid="CR82">2017</xref>) but only rarely compared directly with other orally administered stimulant substances (Hysek et al. <xref ref-type="bibr" rid="CR26">2014b</xref>; Parrott et al. <xref ref-type="bibr" rid="CR50">2011</xref>; Schmid et al. <xref ref-type="bibr" rid="CR62">2014</xref>; Tancer and Johanson <xref ref-type="bibr" rid="CR76">2003</xref>). MDMA induced greater &#x0201c;empathogenic&#x0201d; mood effects, including closeness to others, openness, trust, happiness, and wanting to be with others, compared with oral methylphenidate (Hysek et al. <xref ref-type="bibr" rid="CR25">2014a</xref>; Schmid et al. <xref ref-type="bibr" rid="CR62">2014</xref>). MDMA, but not methylphenidate, impaired the recognition of sad and fearful emotions on the Face Emotion Recognition Task (FERT) and increased biomarkers of serotonergic activity, including plasma concentrations of cortisol, prolactin, and oxytocin (Bedi et al. <xref ref-type="bibr" rid="CR1">2010</xref>; Hysek et al. <xref ref-type="bibr" rid="CR25">2014a</xref>; Kirkpatrick et al. <xref ref-type="bibr" rid="CR32">2014b</xref>; Kuypers et al. <xref ref-type="bibr" rid="CR35">2017</xref>; Schmid et al. <xref ref-type="bibr" rid="CR62">2014</xref>). In contrast, methylphenidate, but not MDMA, increased subjective concentration (Hysek et al. <xref ref-type="bibr" rid="CR25">2014a</xref>; Schmid et al. <xref ref-type="bibr" rid="CR62">2014</xref>) and sexual arousal that was elicited by explicit visual sexual stimuli (Schmid et al. <xref ref-type="bibr" rid="CR64">2015b</xref>). MDMA produced greater drug liking, elation, and good drug effects than amphetamine (Tancer and Johanson <xref ref-type="bibr" rid="CR76">2003</xref>), whereas other studies reported positive mood following methamphetamine but not MDMA administration (Parrott et al. <xref ref-type="bibr" rid="CR50">2011</xref>). However, these studies used only a few outcome measures and did not comprehensively evaluate emotional drug effects. MDMA may have unique empathogenic and prosocial effects that are distinct from classic stimulants (Bedi et al. <xref ref-type="bibr" rid="CR1">2010</xref>; Bershad et al. <xref ref-type="bibr" rid="CR2">2016</xref>; Hysek et al. <xref ref-type="bibr" rid="CR26">2014b</xref>; Kamilar-Britt and Bedi <xref ref-type="bibr" rid="CR30">2015</xref>; Schmid et al. <xref ref-type="bibr" rid="CR62">2014</xref>), but these differences need to be confirmed using blinded administration of MDMA and different stimulants within the same subjects. Therefore, the present cross-over study directly compared the subjective, emotional, autonomic, sexual, and endocrine effects of MDMA, methylphenidate, and modafinil. We expected MDMA to produce acute effects that are distinct from those of methylphenidate and modafinil. The a priori hypotheses defined in the study protocol were that MDMA, but not methylphenidate or modafinil, at the doses used, will produce prosocial and empathic feelings (closeness to others, openness, trust, want to be with other people) and elevate plasma levels of oxytocin (Hysek et al. <xref ref-type="bibr" rid="CR25">2014a</xref>; Hysek et al. <xref ref-type="bibr" rid="CR26">2014b</xref>; Schmid et al. <xref ref-type="bibr" rid="CR62">2014</xref>).</p><p id="Par7">The acute effects of modafinil and methylphenidate are also different. Amphetamine and methylphenidate have greater subjective effects than modafinil (Franke et al. <xref ref-type="bibr" rid="CR13">2017</xref>; Jasinski <xref ref-type="bibr" rid="CR28">2000</xref>; Makris et al. <xref ref-type="bibr" rid="CR42">2007</xref>). In contrast, modafinil may have greater wakefulness-promoting effects than methylphenidate (Jasinski <xref ref-type="bibr" rid="CR28">2000</xref>; Repantis et al. <xref ref-type="bibr" rid="CR57">2010</xref>). In addition to comparisons with MDMA, the present study directly compared the effects of the neuroenhancers methylphenidate and modafinil in healthy subjects, complementing a previous study in stimulant users (Jasinski <xref ref-type="bibr" rid="CR28">2000</xref>).</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Study design</title><p id="Par8">We used a double-blind, placebo-controlled, randomized, cross-over design with four experimental sessions (125&#x000a0;mg MDMA, 60&#x000a0;mg methylphenidate, 600&#x000a0;mg modafinil, and placebo) in 24 subjects. The order of the four experimental sessions was counterbalanced. The washout periods between sessions were at least 7&#x000a0;days. The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Basel and the Swiss Agency for Therapeutic Products (Swissmedic). All of the subjects provided written consent before participating in the study, and they were paid for their participation. The study was registered at <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link> (NCT01951508).</p></sec><sec id="Sec4"><title>Participants</title><p id="Par9">Twenty-four healthy subjects (12 men, 12 women), mean&#x000a0;&#x000b1;&#x000a0;SD age of 22.6&#x000a0;&#x000b1;&#x000a0;3.0&#x000a0;years (range, 19&#x02013;29&#x000a0;years), were recruited from the University of Basel. The inclusion criteria were 18&#x02013;45&#x000a0;years old and body mass index of 18&#x02013;27&#x000a0;kg/m<sup>2</sup>. Subjects with a personal or first-degree-relative history of psychiatric disorders or chronic or acute physical illness were excluded. Additional exclusion criteria were tobacco smoking (&#x0003e;10 cigarettes/day) and a lifetime history of using illicit drugs more than five times, with the exception of occasional cannabis use in the past. In contrast to similar studies in other laboratories, the majority of the participants had never used MDMA or other illicit drugs with the exception of cannabis (Kirkpatrick et al. <xref ref-type="bibr" rid="CR31">2014a</xref>; Kuypers et al. <xref ref-type="bibr" rid="CR35">2017</xref>). Four participants had used MDMA (one&#x02013;three times), two had used cocaine on a single occasion, one had used LSD once, one psilocybin once, and three methylphenidate (once or twice). Four had never used cannabis, 11 had used cannabis 1&#x02013;20 times, and 9 participants had used cannabis &#x0003e;20 times ranging from once/month to 4 times per week. Subjects who used any illicit drugs, including cannabis, within the past 2&#x000a0;months or during the study period were excluded. We performed drug tests at screening and before each test session using TRIAGE 8 (Biosite, San Diego, CA, USA). All female subjects used oral contraceptives and were investigated during the follicular phase of their menstrual cycle (day 2&#x02013;14 after the start of the menstruation) to account for cyclic changes in reactivity, which has been demonstrated for amphetamines (White et al. <xref ref-type="bibr" rid="CR86">2002</xref>).</p></sec><sec id="Sec5"><title>Study procedures</title><p id="Par10">The study included a prescreening telephone interview, a screening visit, four experimental sessions (test days), and an end-of-study visit. The experimental sessions began at 8:45&#x000a0;AM. An indwelling intravenous catheter was placed in an antecubital vein for blood sampling, and baseline measurements were performed. MDMA, methylphenidate, modafinil, or placebo was administered at 9:45&#x000a0;AM. Autonomic and subjective effects were assessed repeatedly throughout the session. Blood was collected to determine endocrine effects and substance concentrations. A functional magnetic resonance imaging (fMRI) scan was performed at 11:15&#x000a0;AM&#x02013;12:15&#x000a0;PM during the expected drug peak effects (Hysek et al. <xref ref-type="bibr" rid="CR26">2014b</xref>; Schmid et al. <xref ref-type="bibr" rid="CR62">2014</xref>; Wong et al. <xref ref-type="bibr" rid="CR87">1998</xref>). The fMRI findings will be published elsewhere. Face emotion recognition was assessed at 12:15&#x000a0;PM. A standardized small lunch was served at 1:15&#x000a0;PM, and the subjects were sent home at 3:45&#x000a0;PM.</p></sec><sec id="Sec6"><title>Study drugs</title><p id="Par11">&#x000b1;MDMA hydrochloride (Lipomed AG, Arlesheim, Switzerland) was prepared as gelatin capsules with mannitol as the filler. Identical placebo (only mannitol) capsules were prepared. MDMA was administered in a single absolute dose of 125&#x000a0;mg corresponding to a relatively high dose of (mean&#x000a0;&#x000b1;&#x000a0;SD) 1.9&#x000a0;&#x000b1;&#x000a0;0.3&#x000a0;mg/kg body weight. This dose of MDMA is in the high range of the doses typically used in clinical research (Kirkpatrick et al. <xref ref-type="bibr" rid="CR33">2015</xref>; Kirkpatrick et al. <xref ref-type="bibr" rid="CR31">2014a</xref>; Kuypers et al. <xref ref-type="bibr" rid="CR35">2017</xref>) but also used in clinical studies in patients with PTSD (Mithoefer et al. <xref ref-type="bibr" rid="CR46">2010</xref>; Oehen et al. <xref ref-type="bibr" rid="CR49">2013</xref>) and is within the dose range that is used recreationally (Brunt et al. <xref ref-type="bibr" rid="CR5">2012</xref>). Immediate-release methylphenidate tablets (10&#x000a0;mg, Ritalin, Novartis AG, Rotkreuz, Switzerland) were encapsulated within opaque gelatin capsules, and identical placebo capsules were prepared. The therapeutic starting dose of methylphenidate is 10&#x000a0;mg and average therapeutic doses are 20&#x02013;30&#x000a0;mg/day. Methylphenidate was administered in a single relatively high dose of 60&#x000a0;mg (Korostenskaja et al. <xref ref-type="bibr" rid="CR34">2008</xref>; Martin et al. <xref ref-type="bibr" rid="CR43">1971</xref>). The subjective and cardiostimulant effects of this dose have previously been assessed on the same tests (Hysek et al. <xref ref-type="bibr" rid="CR26">2014b</xref>) and have also been statistically compared with a lower dose of 40&#x000a0;mg (Schmid et al. <xref ref-type="bibr" rid="CR62">2014</xref>). The doses of MDMA and methylphenidate used were expected to be equivalent regarding their cardiovascular stimulant effects (Hysek et al. <xref ref-type="bibr" rid="CR26">2014b</xref>). Modafinil tablets (100&#x000a0;mg, Teva Pharma AG, Basel, Switzerland) were encapsulated within opaque gelatin capsules, and identical placebo capsules were prepared. The therapeutic starting dose of modafinil is 100&#x000a0;mg and common doses are 400&#x000a0;mg/day. Modafinil was administered in a single high dose of 600&#x000a0;mg. The goal was to use high single doses of all substances with comparable cardiostimulant effects (Hysek et al. <xref ref-type="bibr" rid="CR26">2014b</xref>; Jasinski <xref ref-type="bibr" rid="CR28">2000</xref>) and to maximize the subjective drug effects.</p></sec><sec id="Sec7"><title>Measures</title><sec id="FPar1"><title>Autonomic effects</title><p id="Par12">Blood pressure, heart rate, and tympanic body temperature were repeatedly measured 1&#x000a0;h before and 0, 0.3, 0.6, 1, 1.25, 1.5, 2.5, 3, 4, 5, and 6&#x000a0;h after drug administration as previously described in detail (Hysek et al. <xref ref-type="bibr" rid="CR20">2010</xref>). The peak rate-pressure product (systolic blood pressure&#x000a0;&#x000d7;&#x000a0;heart rate) was the main autonomic outcome measure reflecting the maximal total hemodynamic response to a substance and expected to be comparable across substances at the doses used (Hysek et al. <xref ref-type="bibr" rid="CR26">2014b</xref>; Jasinski <xref ref-type="bibr" rid="CR28">2000</xref>).</p></sec><sec id="FPar2"><title>Subjective effects</title><p id="Par13">Subjective effects were assessed repeatedly using visual analog scales (VASs) 1&#x000a0;h before and 0, 0.3, 0.6, 1, 1.25, 1.5, 2.5, 3, 4, 5, and 6&#x000a0;h after drug administration. The VASs included &#x0201c;any drug effect,&#x0201d; &#x0201c;good drug effect,&#x0201d; &#x0201c;bad drug effect,&#x0201d; &#x0201c;drug liking,&#x0201d; &#x0201c;happy,&#x0201d; &#x0201c;concentration,&#x0201d; &#x0201c;open,&#x0201d; &#x0201c;trust,&#x0201d; &#x0201c;feeling close to others,&#x0201d; &#x0201c;I want to be with other people,&#x0201d; and &#x0201c;I want to hug someone&#x0201d; (Hysek et al. <xref ref-type="bibr" rid="CR25">2014a</xref>). The VASs were presented as 100-mm horizontal lines (0&#x02013;100%), marked from &#x0201c;not at all&#x0201d; on the left to &#x0201c;extremely&#x0201d; on the right. The 60-item Adjective Mood Rating Scale (AMRS; (Janke and Debus <xref ref-type="bibr" rid="CR27">1978</xref>)) and State-Trait Anxiety Inventory (STAI; (Spielberger et al. <xref ref-type="bibr" rid="CR73">1970</xref>)) were administered 1&#x000a0;h before and 1.25, 2.5, and 5&#x000a0;h after drug administration. The German version of the 49-item Addiction Research Center Inventory (ARCI; (Bopp et al. <xref ref-type="bibr" rid="CR3">2005</xref>; Martin et al. <xref ref-type="bibr" rid="CR43">1971</xref>)) was administered 1&#x000a0;h before and 1.25&#x000a0;h after drug administration. The 5-Dimensions of Altered States of Consciousness (5D&#x02013;ASC) scale (Dittrich <xref ref-type="bibr" rid="CR7">1998</xref>; Studerus et al. <xref ref-type="bibr" rid="CR75">2010</xref>) was administered 5&#x000a0;h after drug administration to retrospectively rate the effects of the drugs.</p></sec><sec id="FPar3"><title>Endocrine effects</title><p id="Par14">The plasma levels of prolactin, cortisol, oxytocin, and vasopressin were measured at baseline and 1.5 and 2.5&#x000a0;h after drug administration and analyzed as described previously (Hysek et al. <xref ref-type="bibr" rid="CR23">2012b</xref>; Neumann et al. <xref ref-type="bibr" rid="CR48">2013</xref>).</p></sec></sec><sec id="Sec8"><title>Facial emotion recognition task</title><p id="Par15">We used the FERT, which is sensitive to the effects of MDMA (Bedi et al. <xref ref-type="bibr" rid="CR1">2010</xref>; Hysek et al. <xref ref-type="bibr" rid="CR26">2014b</xref>; Kirkpatrick et al. <xref ref-type="bibr" rid="CR32">2014b</xref>; Schmid et al. <xref ref-type="bibr" rid="CR62">2014</xref>) and methylphenidate (Hysek et al. <xref ref-type="bibr" rid="CR26">2014b</xref>; Schmid et al. <xref ref-type="bibr" rid="CR62">2014</xref>). The task included 10 neutral faces and 160 faces that expressed one of four basic emotions (i.e., happiness, sadness, anger, and fear), with pictures morphed between 0% (neutral) and 100% in 10% steps. Two female and two male pictures were used for each of the four emotions. The stimuli were presented in random order for 500&#x000a0;ms and then were replaced by the rating screen where participants had to indicate the correct emotion. The main outcome measure was accuracy (proportion correct). Additionally, we analyzed whether incorrectly identified emotional expressions were misclassified as neutral or other emotions (Bedi et al. <xref ref-type="bibr" rid="CR1">2010</xref>; Schmid et al. <xref ref-type="bibr" rid="CR62">2014</xref>). The FERT was performed 2.5&#x000a0;h after drug administration.</p></sec><sec id="Sec9"><title>Sexual arousal and desire Inventory</title><p id="Par16">The SADI is a self-report scale that includes 54 items (adjectives or short sentences) and measures subjective sexual arousal and desire (Persson et al. <xref ref-type="bibr" rid="CR52">2016</xref>; Toledano and Pfaus <xref ref-type="bibr" rid="CR79">2006</xref>). Each item is rated from 0 (&#x0201c;does not describe it at all&#x0201d;) to 5 (&#x0201c;describes it perfectly&#x0201d;). The questionnaire includes four overlapping factors: &#x0201c;Evaluative,&#x0201d; &#x0201c;Physiological,&#x0201d; &#x0201c;Negative/Aversive,&#x0201d; and &#x0201c;Motivational.&#x0201d; The &#x0201c;Evaluative&#x0201d; scale consists of 27 items that describe cognitive and emotional aspects (i.e., tempted, passionate, seductive, attractive). The &#x0201c;Physiological&#x0201d; scale consists of 17 items that describe autonomic reactions to sexual arousal (i.e., sensitive to touch, stimulated, excited, heart beats faster). The &#x0201c;Negative/Aversive&#x0201d; scale consists of 17 items that describe aspects that are opposite to sexual arousal (i.e., anxious, displeasure, repulsion, angry). The &#x0201c;Motivational&#x0201d; scale consists of 10 items that are related to the motivation to engage in sexual activity (i.e., driven, urge to satisfy, horny, impatient). The SADI was administered 1&#x000a0;h before and 3&#x000a0;h after drug administration.</p></sec><sec id="Sec10"><title>Substance plasma concentrations</title><p id="Par17">The plasma levels of methylphenidate, modafinil, MDMA, and the MDMA metabolites 3,4-methylenedioxyamphetamine (MDA) and 4-hydroxy-3-methoxymethamphetamine (HMMA) were determined 1&#x000a0;h before and 1, 1.5, 2.5, 3, 4, and 6&#x000a0;h after substance administration using liquid chromatography-mass spectrometry/mass spectrometry as previously described (Hysek et al. <xref ref-type="bibr" rid="CR22">2012a</xref>; Hysek et al. <xref ref-type="bibr" rid="CR26">2014b</xref>). The maximal plasma concentration (<italic>C</italic>
<sub>max</sub>) and time to <italic>C</italic>
<sub>max</sub> (<italic>T</italic>
<sub>max</sub>) were obtained directly from the observed concentration-time curves.</p></sec><sec id="Sec11"><title>Adverse effects</title><p id="Par18">Adverse effects were assessed 1&#x000a0;h before and 6&#x000a0;h (acute) and 24&#x000a0;h (sub-acute) after drug administration using the 66-item List of Complaints (Zerssen <xref ref-type="bibr" rid="CR90">1976</xref>). The scale yields a total adverse effects score and reliably measures physical and general discomfort.</p></sec><sec id="Sec12"><title>Statistical analyses</title><p id="Par19">Repeated measures are expressed as peak effects or peak changes from baseline (<italic>E</italic>
<sub>max</sub>). The data were analyzed using repeated-measures analysis of variance (ANOVA), with drug as the within-subjects factor, followed by Tukey post hoc comparisons based on significant main effects. Some of the VASs data were not normally distributed and were therefore analyzed using Friedman ANOVAs with drug as the within-subject factor, followed by Wilcoxon matched pairs tests. The criterion for significance was <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05. The criterion was adjusted for the multiple comparisons within the VAS and the AMRS using the Bonferroni method.</p></sec></sec><sec id="Sec13"><title>Results</title><p id="Par20">All 24 participants completed all sessions of the study. Autonomic, subjective, and endocrine peak effects and statistics are shown in Table <xref rid="Tab1" ref-type="table">1</xref> and Supplementary Table <xref rid="MOESM1" ref-type="media">S1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Comparison of the acute effects of MDMA, methylphenidate, modafinil, and placebo (<italic>N</italic>&#x000a0;=&#x000a0;24)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="2"/><th>Placebo</th><th>MDMA</th><th>Methylphenidate</th><th>Modafinil</th><th/><th/></tr><tr><th>(mean&#x000a0;&#x000b1;&#x000a0;SEM)</th><th>(mean&#x000a0;&#x000b1;&#x000a0;SEM)</th><th>(mean&#x000a0;&#x000b1;&#x000a0;SEM)</th><th>(mean&#x000a0;&#x000b1;&#x000a0;SEM)</th><th>
<italic>F</italic> 3.69</th><th>
<italic>p</italic>=</th></tr></thead><tbody><tr><td colspan="8">Autonomic effects</td></tr><tr><td>&#x02003;Systolic blood pressure (mm Hg)</td><td>
<italic>E</italic>
<sub>max</sub>
</td><td>135&#x000a0;&#x000b1;&#x000a0;3.0</td><td>152&#x000a0;&#x000b1;&#x000a0;3.2***</td><td>145&#x000a0;&#x000b1;&#x000a0;3.1***#</td><td>143&#x000a0;&#x000b1;&#x000a0;3.4**##</td><td>20.41</td><td>&#x0003c;0.001</td></tr><tr><td>&#x02003;Diastolic blood pressure (mm Hg)</td><td>
<italic>E</italic>
<sub>max</sub>
</td><td>78.8&#x000a0;&#x000b1;&#x000a0;1.6</td><td>88.1&#x000a0;&#x000b1;&#x000a0;1.8***</td><td>84.0&#x000a0;&#x000b1;&#x000a0;1.8**#</td><td>85.7&#x000a0;&#x000b1;&#x000a0;2.0***</td><td>13.24</td><td>&#x0003c;0.001</td></tr><tr><td>&#x02003;Heart rate (beats/min)</td><td>
<italic>E</italic>
<sub>max</sub>
</td><td>73.1&#x000a0;&#x000b1;&#x000a0;2.5</td><td>90.3&#x000a0;&#x000b1;&#x000a0;3.0***</td><td>91.6&#x000a0;&#x000b1;&#x000a0;3.6***</td><td>87.9&#x000a0;&#x000b1;&#x000a0;3.5***</td><td>23.82</td><td>&#x0003c;0.001</td></tr><tr><td>&#x02003;Rate pressure product (beats&#x000b7;mmHg/min)</td><td>
<italic>E</italic>
<sub>max</sub>
</td><td>9603&#x000a0;&#x000b1;&#x000a0;383</td><td>13,377&#x000a0;&#x000b1;&#x000a0;536***</td><td>12,985&#x000a0;&#x000b1;&#x000a0;625***</td><td>12,273&#x000a0;&#x000b1;&#x000a0;667***</td><td>26.15</td><td>&#x0003c;0.001</td></tr><tr><td>&#x02003;Body temperature (&#x000b0;C)</td><td>
<italic>E</italic>
<sub>max</sub>
</td><td>37.3&#x000a0;&#x000b1;&#x000a0;0.1</td><td>37.6&#x000a0;&#x000b1;&#x000a0;0.1**</td><td>37.6&#x000a0;&#x000b1;&#x000a0;0.1**</td><td>37.9&#x000a0;&#x000b1;&#x000a0;0.1***</td><td>12.55</td><td>&#x0003c;0.001</td></tr><tr><td>&#x02003;Pupil size (mm)</td><td>
<italic>E</italic>
<sub>max</sub>
</td><td>6.5&#x000a0;&#x000b1;&#x000a0;0.1</td><td>7.4&#x000a0;&#x000b1;&#x000a0;0.1***</td><td>6.7&#x000a0;&#x000b1;&#x000a0;0.1**###</td><td>6.7&#x000a0;&#x000b1;&#x000a0;0.2*###</td><td>76.11</td><td>&#x0003c;0.001</td></tr><tr><td>&#x02003;Pupil size after light stimulus (mm)</td><td>
<italic>E</italic>
<sub>max</sub>
</td><td>4.7&#x000a0;&#x000b1;&#x000a0;0.1</td><td>6.4&#x000a0;&#x000b1;&#x000a0;0.2***</td><td>4.8&#x000a0;&#x000b1;&#x000a0;0.1###</td><td>4.8&#x000a0;&#x000b1;&#x000a0;0.1###</td><td>148.78</td><td>&#x0003c;0.001</td></tr><tr><td>&#x02003;Constriction amplitude (mm)</td><td>
<italic>E</italic>
<sub>min</sub>
</td><td>1.8&#x000a0;&#x000b1;&#x000a0;0.1</td><td>0.86&#x000a0;&#x000b1;&#x000a0;0.10***</td><td>1.8&#x000a0;&#x000b1;&#x000a0;0.1###</td><td>1.7&#x000a0;&#x000b1;&#x000a0;0.1###</td><td>34.47</td><td>&#x0003c;0.001</td></tr><tr><td colspan="8">Subjective effects</td></tr><tr><td colspan="8">Visual Analog Scale (VAS, %max)</td></tr><tr><td>&#x02003;Any drug effect</td><td>&#x00394;E<sub>max</sub>
</td><td>10.0&#x000a0;&#x000b1;&#x000a0;2.4</td><td>75.3&#x000a0;&#x000b1;&#x000a0;5.1***</td><td>32.8&#x000a0;&#x000b1;&#x000a0;6.8*###</td><td>23.7&#x000a0;&#x000b1;&#x000a0;5.2###</td><td>45.51</td><td>&#x0003c;0.001</td></tr><tr><td>&#x02003;Good drug effect</td><td>&#x00394;E<sub>max</sub>
</td><td>7.5&#x000a0;&#x000b1;&#x000a0;2.5</td><td>73.2&#x000a0;&#x000b1;&#x000a0;5.3***</td><td>35.5&#x000a0;&#x000b1;&#x000a0;7.7**###</td><td>23.9&#x000a0;&#x000b1;&#x000a0;5.4###</td><td>45.68</td><td>&#x0003c;0.001</td></tr><tr><td>&#x02003;Bad drug effect</td><td>&#x00394;E<sub>max</sub>
</td><td>4.2&#x000a0;&#x000b1;&#x000a0;3.3</td><td>12.7&#x000a0;&#x000b1;&#x000a0;3.5</td><td>11.5&#x000a0;&#x000b1;&#x000a0;4.5</td><td>10.3&#x000a0;&#x000b1;&#x000a0;4.9</td><td>10.49</td><td>NS</td></tr><tr><td>&#x02003;Drug liking</td><td>&#x00394;E<sub>max</sub>
</td><td>9.4&#x000a0;&#x000b1;&#x000a0;3.0</td><td>75.5&#x000a0;&#x000b1;&#x000a0;5.5***</td><td>36.3&#x000a0;&#x000b1;&#x000a0;8.2*###</td><td>24.8&#x000a0;&#x000b1;&#x000a0;5.4###</td><td>40.9</td><td>&#x0003c;0.001</td></tr><tr><td>&#x02003;Happy</td><td>&#x00394;E<sub>max</sub>
</td><td>2.7&#x000a0;&#x000b1;&#x000a0;1.2</td><td>31.0&#x000a0;&#x000b1;&#x000a0;3.6***</td><td>10.8&#x000a0;&#x000b1;&#x000a0;3.6##</td><td>8.1&#x000a0;&#x000b1;&#x000a0;2.4###</td><td>41.06</td><td>&#x0003c;0.001</td></tr><tr><td>&#x02003;Concentration</td><td>&#x00394;E<sub>max</sub>
</td><td>&#x02212;6.5&#x000a0;&#x000b1;&#x000a0;1.5</td><td>&#x02212;29.3&#x000a0;&#x000b1;&#x000a0;3.4</td><td>&#x02212;11.6&#x000a0;&#x000b1;&#x000a0;3.6</td><td>&#x02212;13.3&#x000a0;&#x000b1;&#x000a0;3.6</td><td>9.56</td><td>NS</td></tr><tr><td>&#x02003;Open</td><td>&#x00394;E<sub>max</sub>
</td><td>2.4&#x000a0;&#x000b1;&#x000a0;1.0</td><td>19.6&#x000a0;&#x000b1;&#x000a0;3.7**</td><td>11.2&#x000a0;&#x000b1;&#x000a0;3.5*</td><td>9.5&#x000a0;&#x000b1;&#x000a0;2.9</td><td>20.08</td><td>&#x0003c;0.01</td></tr><tr><td>&#x02003;Trust</td><td>&#x00394;E<sub>max</sub>
</td><td>1.5&#x000a0;&#x000b1;&#x000a0;0.9</td><td>24.5&#x000a0;&#x000b1;&#x000a0;4.1**</td><td>8.0&#x000a0;&#x000b1;&#x000a0;3.0##</td><td>8.6&#x000a0;&#x000b1;&#x000a0;3.7#</td><td>24.85</td><td>&#x0003c;0.001</td></tr><tr><td>&#x02003;Feeling close to others</td><td>&#x00394;E<sub>max</sub>
</td><td>1.1&#x000a0;&#x000b1;&#x000a0;0.8</td><td>18.5&#x000a0;&#x000b1;&#x000a0;3.8**</td><td>9.7&#x000a0;&#x000b1;&#x000a0;2.6*#</td><td>5.7&#x000a0;&#x000b1;&#x000a0;2.1#</td><td>24.79</td><td>&#x0003c;0.001</td></tr><tr><td>&#x02003;I want to be with other people</td><td>&#x00394;E<sub>max</sub>
</td><td>3.1&#x000a0;&#x000b1;&#x000a0;1.9</td><td>21.0&#x000a0;&#x000b1;&#x000a0;4.3***</td><td>10.1&#x000a0;&#x000b1;&#x000a0;3.5#</td><td>9.9&#x000a0;&#x000b1;&#x000a0;3.8#</td><td>18.46</td><td>&#x0003c;0.01</td></tr><tr><td>&#x02003;I want to hug someone</td><td>&#x00394;E<sub>max</sub>
</td><td>0.6&#x000a0;&#x000b1;&#x000a0;0.6</td><td>15.1&#x000a0;&#x000b1;&#x000a0;3.6*</td><td>7.0&#x000a0;&#x000b1;&#x000a0;3.3</td><td>3.3&#x000a0;&#x000b1;&#x000a0;2.3#</td><td>23.13</td><td>&#x0003c;0.001</td></tr><tr><td colspan="8">Adjective Mood Rating Scale (AMRS score)</td></tr><tr><td>&#x02003;Well-being</td><td>&#x00394;E<sub>max</sub>
</td><td>0.04&#x000a0;&#x000b1;&#x000a0;0.37</td><td>5.8&#x000a0;&#x000b1;&#x000a0;1.0***</td><td>2.5&#x000a0;&#x000b1;&#x000a0;0.7#</td><td>1.3&#x000a0;&#x000b1;&#x000a0;0.7##</td><td>14.52</td><td>&#x0003c;0.001</td></tr><tr><td>&#x02003;Emotional excitation</td><td>&#x00394;E<sub>max</sub>
</td><td>&#x02212;0.13&#x000a0;&#x000b1;&#x000a0;0.56</td><td>3.0&#x000a0;&#x000b1;&#x000a0;0.9*</td><td>2.6&#x000a0;&#x000b1;&#x000a0;0.8</td><td>1.2&#x000a0;&#x000b1;&#x000a0;0.7</td><td>4.91</td><td>&#x0003c;0.05</td></tr><tr><td>&#x02003;Activity</td><td>&#x00394;E<sub>max</sub>
</td><td>0.79&#x000a0;&#x000b1;&#x000a0;0.45</td><td>2.0&#x000a0;&#x000b1;&#x000a0;0.6</td><td>2.5&#x000a0;&#x000b1;&#x000a0;0.5</td><td>0.50&#x000a0;&#x000b1;&#x000a0;0.4</td><td>3.23</td><td>NS</td></tr><tr><td>&#x02003;Extroversion</td><td>&#x00394;E<sub>max</sub>
</td><td>0.0&#x000a0;&#x000b1;&#x000a0;0.4</td><td>2.3&#x000a0;&#x000b1;&#x000a0;0.6**</td><td>1.3&#x000a0;&#x000b1;&#x000a0;0.5</td><td>1.36&#x000a0;&#x000b1;&#x000a0;0.5</td><td>5.25</td><td>&#x0003c;0.05</td></tr><tr><td>&#x02003;Introversion</td><td>&#x00394;E<sub>max</sub>
</td><td>0.50&#x000a0;&#x000b1;&#x000a0;0.29</td><td>2.4&#x000a0;&#x000b1;&#x000a0;0.5*</td><td>1.3&#x000a0;&#x000b1;&#x000a0;0.4</td><td>0.9&#x000a0;&#x000b1;&#x000a0;0.4</td><td>4.36</td><td>&#x0003c;0.05</td></tr><tr><td>&#x02003;Concentration</td><td>&#x00394;E<sub>max</sub>
</td><td>0.3&#x000a0;&#x000b1;&#x000a0;0.32</td><td>0.46&#x000a0;&#x000b1;&#x000a0;0.46</td><td>1.13&#x000a0;&#x000b1;&#x000a0;0.42</td><td>&#x02212;0.33&#x000a0;&#x000b1;&#x000a0;0.25</td><td>3.05</td><td>NS</td></tr><tr><td colspan="8">State-Trait Anxiety Inventory (state anxiety score)</td></tr><tr><td/><td>
<italic>E</italic>
<sub>max</sub>
</td><td>36.6&#x000a0;&#x000b1;&#x000a0;1.0</td><td>37.6&#x000a0;&#x000b1;&#x000a0;1.4</td><td>42.0&#x000a0;&#x000b1;&#x000a0;1.8*</td><td>39.5&#x000a0;&#x000b1;&#x000a0;1.6</td><td>3.25</td><td>&#x0003c;0.05</td></tr><tr><td/><td>
<italic>E</italic>
<sub>min</sub>
</td><td>32.8&#x000a0;&#x000b1;&#x000a0;0.9</td><td>29.0&#x000a0;&#x000b1;&#x000a0;1***</td><td>34.5&#x000a0;&#x000b1;&#x000a0;1.0###</td><td>32.5&#x000a0;&#x000b1;&#x000a0;1.2#</td><td>6.58</td><td>&#x0003c;0.001</td></tr><tr><td colspan="8">Sexual Arousal and Desire Inventory</td></tr><tr><td>&#x02003;Evaluative</td><td/><td>1.4&#x000a0;&#x000b1;&#x000a0;1.3</td><td>19.5&#x000a0;&#x000b1;&#x000a0;4.3***</td><td>6.5&#x000a0;&#x000b1;&#x000a0;3.4#</td><td>8.4&#x000a0;&#x000b1;&#x000a0;3.6#</td><td>6.98</td><td>&#x0003c;0.001</td></tr><tr><td>&#x02003;Negative/Aversive</td><td/><td>0.04&#x000a0;&#x000b1;&#x000a0;1.3</td><td>&#x02212;0.09&#x000a0;&#x000b1;&#x000a0;1.5</td><td>0.3&#x000a0;&#x000b1;&#x000a0;1.4</td><td>4.9&#x000a0;&#x000b1;&#x000a0;2.6</td><td>1.88</td><td>NS</td></tr><tr><td>&#x02003;Physiological</td><td/><td>1.6&#x000a0;&#x000b1;&#x000a0;0.9</td><td>13.2&#x000a0;&#x000b1;&#x000a0;2.4***</td><td>6.6&#x000a0;&#x000b1;&#x000a0;2.4#</td><td>5.0&#x000a0;&#x000b1;&#x000a0;2.2##</td><td>8.03</td><td>&#x0003c;0.001</td></tr><tr><td>&#x02003;Motivational</td><td/><td>0.4&#x000a0;&#x000b1;&#x000a0;0.6</td><td>4.8&#x000a0;&#x000b1;&#x000a0;1.5*</td><td>1.1&#x000a0;&#x000b1;&#x000a0;1.2</td><td>2.5&#x000a0;&#x000b1;&#x000a0;1.4</td><td>3.22</td><td>&#x0003c;0.05</td></tr><tr><td colspan="8">Hormones</td></tr><tr><td>&#x02003;Cortisol (nmol/L)</td><td>
<italic>E</italic>
<sub>max</sub>
</td><td>630&#x000a0;&#x000b1;&#x000a0;53.5</td><td>942&#x000a0;&#x000b1;&#x000a0;41.5***</td><td>648&#x000a0;&#x000b1;&#x000a0;37.7**###</td><td>653&#x000a0;&#x000b1;&#x000a0;40.5###</td><td>35.55</td><td>&#x0003c;0.001</td></tr><tr><td>&#x02003;Prolactin (mU/L)</td><td>
<italic>E</italic>
<sub>max</sub>
</td><td>334&#x000a0;&#x000b1;&#x000a0;32.7</td><td>1086&#x000a0;&#x000b1;&#x000a0;143***</td><td>295&#x000a0;&#x000b1;&#x000a0;30.9###</td><td>288&#x000a0;&#x000b1;&#x000a0;24.0###</td><td>30.46</td><td>&#x0003c;0.001</td></tr><tr><td>&#x02003;Oxytocin (pg/mL)</td><td>
<italic>E</italic>
<sub>max</sub>
</td><td>5.0&#x000a0;&#x000b1;&#x000a0;1.5</td><td>58.7&#x000a0;&#x000b1;&#x000a0;7.9***</td><td>6.3&#x000a0;&#x000b1;&#x000a0;1.3###</td><td>4.29&#x000a0;&#x000b1;&#x000a0;0.87###</td><td>44.90</td><td>&#x0003c;0.001</td></tr><tr><td>&#x02003;Vasopressin (pg/mL)</td><td>
<italic>E</italic>
<sub>max</sub>
</td><td>4.1&#x000a0;&#x000b1;&#x000a0;0.3</td><td>4.4&#x000a0;&#x000b1;&#x000a0;0.5</td><td>4.23&#x000a0;&#x000b1;&#x000a0;0.67</td><td>3.44&#x000a0;&#x000b1;&#x000a0;0.27</td><td>2.15</td><td>NS</td></tr></tbody></table><table-wrap-foot><p>VAS and AMRS <italic>P</italic> values were Bonferroni adjusted values considering the multiple subscales used (11 and 6 for the VAS and AMRS, respectively)</p><p>
<italic>NS</italic> not significant, <italic>Emax</italic> maximal effect, <italic>&#x00394;Emax</italic> maximal difference from baseline</p><p>*<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05, **<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01, ***<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001 compared with placebo; #<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05, ##<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01, ###<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001 compared with MDMA</p></table-wrap-foot></table-wrap>
</p><sec id="Sec14"><title>Autonomic effects</title><p id="Par21">Drug effects on vital signs over time are shown in Fig. <xref rid="Fig1" ref-type="fig">1</xref>, and peak effects are shown in Table <xref rid="Tab1" ref-type="table">1</xref>. All active substances produced comparable and significant increases in body temperature and similar hemodynamic stimulation, considering the similar increase in the rate-pressure products compared with placebo. MDMA markedly and significantly increased pupil size in the dark and after a light stimulus and decreased the constriction amplitude. Methylphenidate and modafinil produced only very small but significant increases in pupil size in the dark. MDMA produced significantly greater alterations in pupil function than methylphenidate and modafinil, including markedly greater pupil size in the dark and significantly lower responses to a light stimulus (Supplementary Fig. <xref rid="MOESM2" ref-type="media">S1</xref>, Table <xref rid="Tab1" ref-type="table">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Autonomic responses to MDMA, methylphenidate, modafinil, and placebo. All active treatments increased systolic and diastolic blood pressure, heart rate, and body temperature. MDMA produced slightly higher increases in blood pressure than methylphenidate and modafinil. However, the overall hemodynamic response, expressed as the rate pressure product, similarly increased after all active treatments compared with placebo. The data are expressed as the mean&#x000a0;&#x000b1;&#x000a0;SEM in 24 subjects. The substances were administered at <italic>t</italic>&#x000a0;=&#x000a0;0</p></caption><graphic xlink:href="213_2017_4650_Fig1_HTML" id="MO1"/></fig>
</p></sec><sec id="Sec15"><title>Subjective effects</title><p id="Par22">Subjective drug effects over time are shown in Fig. <xref rid="Fig2" ref-type="fig">2</xref> and Fig. <xref rid="Fig3" ref-type="fig">3</xref>, and peak responses are shown in Table <xref rid="Tab1" ref-type="table">1</xref> and Supplementary Table <xref rid="MOESM1" ref-type="media">S1</xref>. On the VASs (Fig. <xref rid="Fig2" ref-type="fig">2</xref>), MDMA increased ratings for any drug effect, good drug effect, drug liking, happiness, open, trust, feeling close to others, I want to be with other people, and I want to hug someone compared with placebo. Methylphenidate produced significant increases in any drug effect, good drug effect, and drug liking but only very small increases in ratings of open, and feeling close to others compared with placebo. Modafinil produced no significant subjective effects compared with placebo. MDMA increased ratings for any drug effect, good drug effect, drug liking, happy, trust, feeling close to others, and want to be with other people more than methylphenidate or modafinil. On the AMRS (Fig. <xref rid="Fig3" ref-type="fig">3</xref>), MDMA increased well-being, emotional excitation, extraversion, and introversion compared with placebo. Methylphenidate and modafinil had no effects on the AMRS. MDMA increased well-being more than methylphenidate or modafinil. On the STAI (Fig. <xref rid="Fig3" ref-type="fig">3</xref>), MDMA reduced state anxiety, methylphenidate increased anxiety, and modafinil had no effect. On the ARCI (Supplementary Table <xref rid="MOESM1" ref-type="media">S1</xref>), MDMA increased amphetamine-group, morphine, and pentobarbital-chlorpromazine-alcohol group ratings compared with placebo. Methylphenidate increased amphetamine and benzedrine group ratings compared with placebo. Modafinil had no significant effects on the ARCI. MDMA increased morphine and pentobarbital-chlorpromazine-alcohol group ratings significantly more than methylphenidate and modafinil. On the 5D-ASC scale (Supplementary Table <xref rid="MOESM1" ref-type="media">S1</xref>), MDMA produced effects on oceanic boundlessness and anxious ego dissolution. Methylphenidate and modafinil had no effects on any of the 5D-ASC scales.<fig id="Fig2"><label>Fig. 2</label><caption><p>Subjective effects of MDMA, methylphenidate, modafinil, and placebo on the VASs. MDMA produced greater subjective effect ratings on most VASs compared with methylphenidate and modafinil. MDMA produced greater any drug effects, good drug effects, drug liking, happiness, trust, and feeling close to others than methylphenidate and modafinil. None of the substances produced significant bad drug effects compared with placebo. Modafinil did not produce any significant subjective effects compared with placebo. The data are expressed as the mean&#x000a0;&#x000b1;&#x000a0;SEM in 24 subjects. The substances were administered at <italic>t</italic>&#x000a0;=&#x000a0;0</p></caption><graphic xlink:href="213_2017_4650_Fig2_HTML" id="MO2"/></fig>
<fig id="Fig3"><label>Fig. 3</label><caption><p>On the AMRS, MDMA significantly increased ratings of well-being, emotional excitation, extroversion, and introversion. Methylphenidate and modafinil produced no effects on any of the AMRS scales. On the STAI, MDMA decreased state anxiety, and methylphenidate increased state anxiety. The data are expressed as the mean&#x000a0;&#x000b1;&#x000a0;SEM in 24 subjects. The substances were administered at <italic>t</italic>&#x000a0;=&#x000a0;0</p></caption><graphic xlink:href="213_2017_4650_Fig3_HTML" id="MO3"/></fig>
</p></sec><sec id="Sec16"><title>Endocrine effects</title><p id="Par23">MDMA increased plasma concentrations of cortisol, prolactin, and oxytocin compared with placebo and all of the other active treatments (Fig. <xref rid="Fig4" ref-type="fig">4</xref>, Table <xref rid="Tab1" ref-type="table">1</xref>). Methylphenidate produced a slight increase in cortisol concentrations, and modafinil had no effect. None of the active treatments increased vasopressin concentrations.<fig id="Fig4"><label>Fig. 4</label><caption><p>Endocrine effects of MDMA, methylphenidate, modafinil, and placebo. MDMA increased levels of cortisol, prolactin, and oxytocin compared with placebo. Methylphenidate produced a weak but significant increase in cortisol compared with placebo. Modafinil had no endocrine effects. The data are expressed as the mean&#x000a0;&#x000b1;&#x000a0;SEM in 24 subjects. The substances were administered at <italic>t</italic>&#x000a0;=&#x000a0;0</p></caption><graphic xlink:href="213_2017_4650_Fig4_HTML" id="MO4"/></fig>
</p></sec><sec id="Sec17"><title>Facial emotion recognition</title><p id="Par24">The effects of MDMA, methylphenidate, and modafinil on the FERT are shown in Fig. <xref rid="Fig5" ref-type="fig">5</xref>. Complete datasets were unavailable for two subjects because of technical reasons. The ANOVA revealed a significant main effect of drug on the decoding accuracy of fearful faces (<italic>F</italic>
<sub>3,63</sub>&#x000a0;=&#x000a0;7.38 <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). The post hoc tests showed that MDMA significantly impaired the recognition of fearful faces compared with placebo (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001), methylphenidate (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01), and modafinil (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05). There was a significant main effect of drug on misclassification of emotions as happy (<italic>F</italic>
<sub>3,63</sub>&#x000a0;=&#x000a0;3.35 <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05). MDMA significantly increased the misclassification of emotions as happy compared with placebo (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05). In contrast, methylphenidate (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05) and modafinil (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05) increased misclassifications of emotions as angry (main effect of drug: <italic>F</italic>
<sub>3,63</sub>&#x000a0;=&#x000a0;3.38 <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05). However, methylphenidate and modafinil did not alter emotion recognition accuracy for any of the emotions.<fig id="Fig5"><label>Fig. 5</label><caption><p>On the Facial Emotion Recognition Task, MDMA significantly impaired the recognition of fearful faces compared with placebo. Methylphenidate and modafinil did not significantly alter emotion recognition. The data are expressed as the mean&#x000a0;&#x000b1;&#x000a0;SEM in 22 subjects</p></caption><graphic xlink:href="213_2017_4650_Fig5_HTML" id="MO5"/></fig>
</p></sec><sec id="Sec18"><title>Sexual arousal and desire</title><p id="Par25">Data from one subject were missing. Only MDMA increased scores on the &#x0201c;Evaluative&#x0201d; (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001), &#x0201c;Physiological&#x0201d; (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001), and &#x0201c;Motivational&#x0201d; (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05) scales compared with placebo, but it did not influence scores on the &#x0201c;Negative/Aversive&#x0201d; scale (Table <xref rid="Tab1" ref-type="table">1</xref>). MDMA produced significantly higher ratings on the &#x0201c;Physiological&#x0201d; factor items &#x0201c;tingly all over,&#x0201d; &#x0201c;sensitive to touch,&#x0201d; &#x0201c;enthusiastic,&#x0201d; &#x0201c;warm all over,&#x0201d; &#x0201c;flushed,&#x0201d; &#x0201c;heart beats faster,&#x0201d; and &#x0201c;seductive&#x0201d; compared with placebo. MDMA produced significantly higher ratings on the &#x0201c;Evaluative&#x0201d; factor items &#x0201c;enthusiastic,&#x0201d; &#x0201c;warm all over,&#x0201d; &#x0201c;passionate,&#x0201d; &#x0201c;sensual,&#x0201d; &#x0201c;pleasure,&#x0201d; &#x0201c;heart beats faster,&#x0201d; &#x0201c;happy,&#x0201d; &#x0201c;powerful,&#x0201d; and &#x0201c;forget about all else&#x0201d; compared with placebo MDMA produced significantly higher ratings on the &#x0201c;Motivational&#x0201d; factor item &#x0201c;anticipatory&#x0201d; compared with placebo.</p></sec><sec id="Sec19"><title>Substance plasma concentrations</title><p id="Par26">The concentration-time curves for methylphenidate, modafinil, MDMA, MDA, and HMMA are shown in Supplementary Fig. <xref rid="Fig6" ref-type="supplementary-material">S2</xref>. The <italic>C</italic>
<sub>max</sub> values for MDMA, MDA, and HMMA were 192&#x000a0;&#x000b1;&#x000a0;8.7, 9.1&#x000a0;&#x000b1;&#x000a0;0.4, and 69.1&#x000a0;&#x000b1;&#x000a0;10.0&#x000a0;ng/ml, respectively. The <italic>T</italic>
<sub>max</sub> values were 3.7&#x000a0;&#x000b1;&#x000a0;0.3, 5.7&#x000a0;&#x000b1;&#x000a0;0.2, and 4.2&#x000a0;&#x000b1;&#x000a0;0.3&#x000a0;h, respectively. The <italic>C</italic>
<sub>max</sub> values for methylphenidate and modafinil were 27.0&#x000a0;&#x000b1;&#x000a0;2.1 and 13.2&#x000a0;&#x000b1;&#x000a0;0.5&#x000a0;&#x003bc;g/ml, respectively. The <italic>T</italic>
<sub>max</sub> values were 3.2&#x000a0;&#x000b1;&#x000a0;0.3 and 3.3&#x000a0;&#x000b1;&#x000a0;0.3&#x000a0;h, respectively.</p></sec><sec id="Sec20"><title>Adverse effects</title><p id="Par27">On the List of Complaints, MDMA, methylphenidate, and modafinil produced significant and comparable acute adverse effects (up to 6&#x000a0;h) compared with placebo (Supplementary Table <xref rid="MOESM1" ref-type="media">S1</xref>). The most frequent acute complaints were lack of appetite, dry mouth, and headache. Only modafinil produced significant adverse effects that lasted up to 24&#x000a0;h (mostly insomnia, headache, and lack or appetite). There were no severe adverse effects.</p></sec></sec><sec id="Sec21"><title>Discussion</title><p id="Par28">The main finding of the present study was that oral administration of MDMA produced acute subjective, emotional, sensual/sexual, and endocrine effects that were clearly distinct from those of the stimulant drugs methylphenidate and modafinil at oral doses that produced comparable sympathomimetic stimulant effects. The acute effects of MDMA (Dumont et al. <xref ref-type="bibr" rid="CR9">2009</xref>; Farre et al. <xref ref-type="bibr" rid="CR10">2004</xref>; Hysek et al. <xref ref-type="bibr" rid="CR21">2011</xref>; Kirkpatrick et al. <xref ref-type="bibr" rid="CR32">2014b</xref>; Liechti et al. <xref ref-type="bibr" rid="CR38">2001</xref>; Vollenweider et al. <xref ref-type="bibr" rid="CR84">1998</xref>), methylphenidate (Hysek et al. <xref ref-type="bibr" rid="CR26">2014b</xref>; Schmid et al. <xref ref-type="bibr" rid="CR64">2015b</xref>; Schmid et al. <xref ref-type="bibr" rid="CR62">2014</xref>), and modafinil (Jasinski <xref ref-type="bibr" rid="CR28">2000</xref>; Rush et al. <xref ref-type="bibr" rid="CR60">2002</xref>; Turner et al. <xref ref-type="bibr" rid="CR80">2003</xref>; Wong et al. <xref ref-type="bibr" rid="CR88">1999</xref>) have been previously described in healthy subjects. The present study further compared their acute responses within the same study and within the same subjects, thus providing direct and valid comparisons. The use of four drug conditions in the within-subject study eliminated any between-subject or between-study differences in comparisons of drug characteristics, and all drugs were administered blind in both active and passive control conditions. The primary research question was whether MDMA is simply a stimulant or whether it has unique namely prosocial and empathogenic effects that are distinct from other stimulants (Bershad et al. <xref ref-type="bibr" rid="CR2">2016</xref>). The present study clearly indicated that MDMA has a different effect profile than the stimulant methylphenidate at the doses used, supporting previous, albeit less rigorous, study findings (Bershad et al. <xref ref-type="bibr" rid="CR2">2016</xref>; Hysek et al. <xref ref-type="bibr" rid="CR26">2014b</xref>; Schmid et al. <xref ref-type="bibr" rid="CR64">2015b</xref>; Schmid et al. <xref ref-type="bibr" rid="CR62">2014</xref>). Specifically, MDMA increased well-being, good drug effects, drug liking, happiness, trust, feelings of closeness to others, and wanting to be with others, and reduced state anxiety compared with methylphenidate and modafinil at the doses used. The distinct mood effects of MDMA were congruent with its effects on the FERT, including reductions of fear recognition and more misclassifications of emotions as happy. MDMA, but not methylphenidate, has previously been shown to reduce fear recognition on the FERT (Bedi et al. <xref ref-type="bibr" rid="CR1">2010</xref>; Hysek et al. <xref ref-type="bibr" rid="CR26">2014b</xref>; Kirkpatrick et al. <xref ref-type="bibr" rid="CR32">2014b</xref>; Schmid et al. <xref ref-type="bibr" rid="CR62">2014</xref>). Additionally, MDMA, but not methylphenidate or modafinil, strongly increased endocrine markers of acutely increased serotonergic activity, including cortisol and prolactin (Seifritz et al. <xref ref-type="bibr" rid="CR67">1996</xref>; Sommers et al. <xref ref-type="bibr" rid="CR72">1994</xref>; Strajhar et al. <xref ref-type="bibr" rid="CR74">2016</xref>). MDMA, but not methylphenidate or modafinil, also markedly increased pupil size at rest and after light stimulation, which is consistent with a previous study (Hysek and Liechti <xref ref-type="bibr" rid="CR19">2012</xref>) and other serotonergic substances (Schmid et al. <xref ref-type="bibr" rid="CR63">2015a</xref>). On the ARCI, methylphenidate and modafinil produced significantly fewer sedating effects than MDMA, which is consistent with their greater stimulant-type properties.</p><p id="Par29">Pharmacologically, MDMA (Hysek et al. <xref ref-type="bibr" rid="CR24">2012c</xref>; White et al. <xref ref-type="bibr" rid="CR85">1996</xref>), methylphenidate (Han and Gu <xref ref-type="bibr" rid="CR15">2006</xref>; Rothman et al. <xref ref-type="bibr" rid="CR58">2001</xref>; Schmeichel and Berridge <xref ref-type="bibr" rid="CR61">2013</xref>), and modafinil (Madras et al. <xref ref-type="bibr" rid="CR39">2006</xref>; Rowley et al. <xref ref-type="bibr" rid="CR59">2014</xref>) all stimulate the noradrenergic system and consistently produced overall similar cardiostimulant effects in the present study. Additionally, MDMA releases serotonin (Hysek et al. <xref ref-type="bibr" rid="CR24">2012c</xref>; White et al. <xref ref-type="bibr" rid="CR85">1996</xref>) and oxytocin (Dumont et al. <xref ref-type="bibr" rid="CR9">2009</xref>; Hysek et al. <xref ref-type="bibr" rid="CR23">2012b</xref>; Hysek et al. <xref ref-type="bibr" rid="CR25">2014a</xref>; Kuypers et al. <xref ref-type="bibr" rid="CR35">2017</xref>; Schmid et al. <xref ref-type="bibr" rid="CR62">2014</xref>; Thompson et al. <xref ref-type="bibr" rid="CR78">2007</xref>), whereas methylphenidate and modafinil act as dopamine uptake inhibitors (Madras et al. <xref ref-type="bibr" rid="CR39">2006</xref>; Rothman et al. <xref ref-type="bibr" rid="CR58">2001</xref>). Consistent with the different pharmacological profiles of these substances, MDMA exerted distinct subjective effects across all of our rating scales (VASs, AMRS, ARCI, 5D-ASC, and SADI) compared with methylphenidate and modafinil at the doses used. Consistent with the present study, we previously reported greater well-being, happiness, extroversion, and feelings of closeness after 125&#x000a0;mg MDMA administration compared with 60&#x000a0;mg methylphenidate (Hysek et al. <xref ref-type="bibr" rid="CR26">2014b</xref>) and after 75&#x000a0;mg MDMA administration compared with 40&#x000a0;mg methylphenidate (Schmid et al. <xref ref-type="bibr" rid="CR62">2014</xref>).</p><p id="Par30">In the present study, MDMA increased circulating concentrations of cortisol, prolactin, and oxytocin as previously shown for different doses of MDMA (Harris et al. <xref ref-type="bibr" rid="CR17">2002</xref>; Hysek et al. <xref ref-type="bibr" rid="CR23">2012b</xref>; Hysek et al. <xref ref-type="bibr" rid="CR25">2014a</xref>; Joyce et al. <xref ref-type="bibr" rid="CR29">1986</xref>; Kirkpatrick et al. <xref ref-type="bibr" rid="CR32">2014b</xref>; Mas et al. <xref ref-type="bibr" rid="CR44">1999</xref>; Schmid et al. <xref ref-type="bibr" rid="CR62">2014</xref>; Seibert et al. <xref ref-type="bibr" rid="CR66">2014</xref>). MDMA did not alter plasma concentrations of vasopressin, which is consistent with previous studies that reported no change in the concentrations of the vasopressin precursor copeptin (Hysek et al. <xref ref-type="bibr" rid="CR25">2014a</xref>; Schmid et al. <xref ref-type="bibr" rid="CR62">2014</xref>). In contrast, higher levels of vasopressin following MDMA administration were reported in some earlier studies (Forsling et al. <xref ref-type="bibr" rid="CR11">2001</xref>; Henry et al. <xref ref-type="bibr" rid="CR18">1998</xref>), and one study reported higher concentrations of the vasopressin precursor copeptin in females (Simmler et al. <xref ref-type="bibr" rid="CR69">2011</xref>). Methylphenidate only slightly increased plasma concentrations of cortisol in the present study, which is consistent with no or weak effects of methylphenidate that were reported in other studies (Hysek et al. <xref ref-type="bibr" rid="CR26">2014b</xref>; Joyce et al. <xref ref-type="bibr" rid="CR29">1986</xref>; Schmid et al. <xref ref-type="bibr" rid="CR62">2014</xref>; Seibert et al. <xref ref-type="bibr" rid="CR66">2014</xref>). Modafinil had no effects on plasma cortisol, prolactin, oxytocin, or vasopressin concentrations, which is consistent with previous reports for cortisol (Brun et al. <xref ref-type="bibr" rid="CR4">1998</xref>). Altogether, the main endocrine finding of the present study was that only MDMA produced marked increases in cortisol, prolactin, and oxytocin concentrations, which is consistent with similar effects of other serotonergic substances (Schmid et al. <xref ref-type="bibr" rid="CR63">2015a</xref>; Seibert et al. <xref ref-type="bibr" rid="CR66">2014</xref>; Seifritz et al. <xref ref-type="bibr" rid="CR67">1996</xref>; Strajhar et al. <xref ref-type="bibr" rid="CR74">2016</xref>).</p><p id="Par31">The present study used a relatively high dose of modafinil (600&#x000a0;mg), which did not produce significant or relevant subjective effects despite pronounced cardiostimulant and adverse effects, including insomnia, that lasted up to 24&#x000a0;h. Similarly, modafinil produced no subjective mood effects at doses of 100&#x02013;400&#x000a0;mg (Franke et al. <xref ref-type="bibr" rid="CR13">2017</xref>; Muller et al. <xref ref-type="bibr" rid="CR47">2013</xref>; Scoriels et al. <xref ref-type="bibr" rid="CR65">2011</xref>; Turner et al. <xref ref-type="bibr" rid="CR80">2003</xref>). However, modafinil increased misclassifications of emotions as angry on the FERT. Higher subjective anxiety and aggression were reported after administration of 100 and 200&#x000a0;mg modafinil in young (Randall et al. <xref ref-type="bibr" rid="CR54">2003</xref>) but not middle-aged (Randall et al. <xref ref-type="bibr" rid="CR55">2004</xref>) healthy volunteers. Modafinil improved the recognition of sad faces in psychotic patients (Scoriels et al. <xref ref-type="bibr" rid="CR65">2011</xref>), a finding that was not replicated in the present study in healthy subjects. Consistent with its use as a promoter of wakefulness, 100 and 200&#x000a0;mg modafinil increased alertness in healthy subjects in another study (Turner et al. <xref ref-type="bibr" rid="CR80">2003</xref>). Compared with the present study that used a relatively high dose of 600&#x000a0;mg, modafinil had moderate hemodynamic effects at doses of 100&#x02013;200&#x000a0;mg (Turner et al. <xref ref-type="bibr" rid="CR81">2004</xref>; Turner et al. <xref ref-type="bibr" rid="CR80">2003</xref>).</p><p id="Par32">In contrast to modafinil, methylphenidate produced significant subjective good drug effects and drug liking and produced moderate increases in feeling open and close to others compared with placebo. In contrast to the effects of MDMA, methylphenidate increased STAI state anxiety and tended to increase subjective concentration, which is consistent with its stimulant properties and use as a cognitive enhancer (Liakoni et al. <xref ref-type="bibr" rid="CR36">2015</xref>; Maier et al. <xref ref-type="bibr" rid="CR41">2015</xref>; Maier et al. <xref ref-type="bibr" rid="CR40">2013</xref>).</p><p id="Par33">In the present study and at the doses used, MDMA, but not methylphenidate or modafinil, increased ratings of sexual arousal and desire on the SADI. This finding was unexpected because dopaminergic stimulants, including cocaine, methamphetamine, and methylphenidate, have been previously shown to increase sexual desire and arousal (Frohmader et al. <xref ref-type="bibr" rid="CR14">2010</xref>; Rawson et al. <xref ref-type="bibr" rid="CR56">2002</xref>; Schmid et al. <xref ref-type="bibr" rid="CR64">2015b</xref>; Semple et al. <xref ref-type="bibr" rid="CR68">2002</xref>). Interestingly, intravenous (Volkow et al. <xref ref-type="bibr" rid="CR83">2007</xref>) but not oral (Volkow et al. <xref ref-type="bibr" rid="CR83">2007</xref>) administration of methylphenidate enhanced self-reported sexual desire, which is consistent with the lack of sexual stimulant effects of oral methylphenidate that was observed in the present study. We previously reported that methylphenidate, but not MDMA, increased sexual arousal that was elicited by explicit visual sexual stimuli (Schmid et al. <xref ref-type="bibr" rid="CR64">2015b</xref>). The SADI is very different from the test that was used in the previous study. No stimuli were presented, and subjects simply rated the intensity of various sensations that are typically related to sexual stimulation but without a specific sexual context or related stimuli. MDMA increased many sensations that comprise the &#x0201c;Evaluative&#x0201d; and &#x0201c;Physiological&#x0201d; factors of the SADI, including ratings of enthusiastic, happy, sensual, pleasure, warm all over, and heart beats faster, in a potentially nonspecific sexually related manner. Although the subjects were instructed to make ratings on the SADI specifically with regard to sexual arousal and desire, their ratings may have been confounded by direct somatic and subjective drug effects of MDMA that are unrelated to sexual stimulation. Thus, one may argue that MDMA produced many physiological effects that also coincide with sexual arousal. Other studies reported increases in sexual arousal after methylphenidate but not MDMA administration (Frohmader et al. <xref ref-type="bibr" rid="CR14">2010</xref>; Schmid et al. <xref ref-type="bibr" rid="CR64">2015b</xref>; Volkow et al. <xref ref-type="bibr" rid="CR83">2007</xref>). MDMA users report inconsistent effects on sexual arousal and desire (McElrath <xref ref-type="bibr" rid="CR45">2005</xref>; Passie et al. <xref ref-type="bibr" rid="CR51">2005</xref>; Theall et al. <xref ref-type="bibr" rid="CR77">2006</xref>). MDMA appears to enhance pleasurable sensations, touch, and physical closeness rather than actual sexual engagement, and it reportedly impairs sexual performance (Frohmader et al. <xref ref-type="bibr" rid="CR14">2010</xref>; Passie et al. <xref ref-type="bibr" rid="CR51">2005</xref>; Theall et al. <xref ref-type="bibr" rid="CR77">2006</xref>; Zemishlany et al. <xref ref-type="bibr" rid="CR89">2001</xref>). Remaining unclear is whether MDMA produces actual sexual arousal or heightened motivation to engage in sexual activity.</p><p id="Par34">The present study has limitations. We mainly used only one dose of each substance. It is difficult if not impossible to compare active substances if only one dose is used. Thus, the observed differences between drugs were seen at the doses used in this study but may not be present at different doses. However, dose-effect relationships show <italic>E</italic>
<sub>max</sub> curve characteristics (Hysek et al. <xref ref-type="bibr" rid="CR24">2012c</xref>) and we used single but relatively high doses of all drugs expected to result in subjective drug effects close to <italic>E</italic>
<sub>max</sub> based on previous studies (Hysek et al. <xref ref-type="bibr" rid="CR22">2012a</xref>; Hysek et al. <xref ref-type="bibr" rid="CR24">2012c</xref>). MDMA was used at an average dose of 1.9&#x000a0;mg/kg resulting in high mean peak plasma concentrations of 192&#x000a0;ng/ml clearly above the EC<sub>50</sub> values of 44 and 93&#x000a0;ng/ml MDMA for the cardiostimulant and subjective effects, respectively (Hysek et al. <xref ref-type="bibr" rid="CR22">2012a</xref>; Hysek et al. <xref ref-type="bibr" rid="CR24">2012c</xref>). Thus, it can be assumed that near-maximal effects were reached at the MDMA dose used in the present study. Similarly, the single doses of methylphenidate and modafinil were high (sixfold the therapeutic starting doses for both substances), and plasma concentrations of methylphenidate and modafinil were twofold higher compared to those in another study using lower doses (Franke et al. <xref ref-type="bibr" rid="CR13">2017</xref>). Importantly, all of the drugs produced comparable overall sympathomimetic stimulation as reflected by the similar increase in the peak rate-pressure product and consistent with our attempt to match the doses based on previous data (Hysek et al. <xref ref-type="bibr" rid="CR26">2014b</xref>; Jasinski <xref ref-type="bibr" rid="CR28">2000</xref>) to produce similar cardiovascular effects. The distinct effects of MDMA and the other two stimulants were seen at the doses used in the present study. However, similarly distinct profiles were reported for MDMA and methylphenidate using identical and also lower doses of both substances and including also dose-response analyses (Hysek et al. <xref ref-type="bibr" rid="CR26">2014b</xref>; Schmid et al. <xref ref-type="bibr" rid="CR62">2014</xref>). The plasma concentration-time curves of all substances and metabolites measured in the present study were in the expected range based on pharmacokinetic data from other studies (de la Torre et al. <xref ref-type="bibr" rid="CR6">2000</xref>; Wong et al. <xref ref-type="bibr" rid="CR87">1998</xref>). The <italic>C</italic>
<sub>max</sub> was similar, but the mean <italic>T</italic>
<sub>max</sub> (3.2&#x000a0;h) of methylphenidate was longer compared with our previous study (2.3&#x000a0;h) (Hysek et al. <xref ref-type="bibr" rid="CR26">2014b</xref>). Importantly, <italic>T</italic>
<sub>max</sub> values were comparable for all substances used in the present study. Nevertheless, it should be acknowledged that comparisons across substances could be biased by differences in dose and pharmacokinetics.</p><p id="Par35">Another issue relates to the use of many psychometric scales in the present study with the intention to more comprehensively and sensitively describe and compare the effects of the psychoactive substances. This may have increased the risk of change findings. However, the primary study hypothesis of greater socioemotional effects of MDMA compared to methylphenidate and modafinil at the doses used was confirmed. However, the differential effects of the substances on the STAI, ARCI, and SADI should be regarded as exploratory.</p><p id="Par36">In conclusion, MDMA produced acute subjective, emotional, and endocrine effects that were distinct from those of methylphenidate and modafinil at the doses used, which is consistent with their different pharmacological profiles. Modafinil produced acute sympathomimetic stimulation that was comparable to methylphenidate and MDMA, but modafinil produced no emotional or subjective effects at the relatively high dose used.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec22"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="213_2017_4650_MOESM1_ESM.xlsx"><label>Table S1</label><caption><p>Subjective and adverse effects of MDMA, methylphenidate, modafinil, and placebo (<italic>N</italic>&#x000a0;=&#x000a0;24). (XLSX 15&#x000a0;kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="213_2017_4650_MOESM2_ESM.gif"><label>Figure S1</label><caption><p>MDMA markedly increased pupil size in the dark and after a light stimulus and reduced pupillary constriction in response to light. Methylphenidate and modafinil only slightly increased pupil size in the dark and had no effect on pupillary constriction in response to light. The data are expressed as the mean&#x000a0;&#x000b1;&#x000a0;SEM in 24 subjects. The substances were administered at <italic>t</italic>&#x000a0;=&#x000a0;0. (GIF 66&#x000a0;kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="213_2017_4650_MOESM3_ESM.tif"><caption><p>High Resolution Image (TIFF 157&#x000a0;kb)</p></caption></media></supplementary-material>
<supplementary-material id="Fig6" content-type="local-data"><media id="MOESM4" xlink:href="213_2017_4650_MOESM4_ESM.gif"><label>Figure S2</label><caption><p>Plasma concentration vs. time profiles of methylphenidate, modafinil, MDMA, and the MDMA metabolites 3,4-methylenedioxyamphetamine (MDA) and 4-hydroxy-3-methoxymethamphetamine (HMMA). Peak plasma levels were reached 3.2&#x000a0;&#x000b1;&#x000a0;0.3&#x000a0;h, 3.3&#x000a0;&#x000b1;&#x000a0;0.3&#x000a0;h, and 3.7&#x000a0;&#x000b1;&#x000a0;0.3&#x000a0;h after methylphenidate, modafinil, and MDMA administration, respectively. The data are expressed as the mean&#x000a0;&#x000b1;&#x000a0;SEM in 24 subjects. The substances were administered at <italic>t</italic>&#x000a0;=&#x000a0;0. (GIF 38&#x000a0;kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="213_2017_4650_MOESM5_ESM.tif"><caption><p>High Resolution Image (TIFF 106&#x000a0;kb)</p></caption></media></supplementary-material>
</p></sec></sec></body><back><fn-group><fn><p>The study was registered at <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link> (NCT01951508).</p></fn><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (doi:10.1007/s00213-017-4650-5) contains supplementary material, which is available to authorized users.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors acknowledge the assistance of Samuel Harder and Niklaus Denier in study management, Urs Duthaler and Anna Rickli in the measurement of drug plasma concentrations, and Michael Arends for text editing.</p></ack><notes notes-type="COI-statement"><title>Compliance with ethical standards</title><p>The study was conducted in accordance with the Declaration of Helsinki and approved by the local ethics committee. All of the subjects provided written consent before participating in the study.</p><sec id="FPar4"><title>Conflict of interest</title><p id="Par37">The authors declare that they have no conflict of interest.</p></sec><sec id="FPar5"><title>Funding</title><p id="Par38">This work was supported by the Swiss National Science Foundation (grant no. 320030_170249 to MEL and SB) and the University of Basel (to FM).</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bedi</surname><given-names>G</given-names></name><name><surname>Hyman</surname><given-names>D</given-names></name><name><surname>de Wit</surname><given-names>H</given-names></name></person-group><article-title>Is ecstasy an &#x0201c;empathogen&#x0201d;? Effects of &#x000b1;3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others</article-title><source>Biol Psychiatry</source><year>2010</year><volume>68</volume><fpage>1134</fpage><lpage>1140</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2010.08.003</pub-id><pub-id pub-id-type="pmid">20947066</pub-id></element-citation></ref><ref id="CR2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bershad</surname><given-names>AK</given-names></name><name><surname>Miller</surname><given-names>MA</given-names></name><name><surname>Baggott</surname><given-names>MJ</given-names></name><name><surname>de Wit</surname><given-names>H</given-names></name></person-group><article-title>The effects of MDMA on socio-emotional processing: does MDMA differ from other stimulants?</article-title><source>J Psychopharmacol</source><year>2016</year><volume>30</volume><fpage>1248</fpage><lpage>1258</lpage><pub-id pub-id-type="doi">10.1177/0269881116663120</pub-id><pub-id pub-id-type="pmid">27562198</pub-id></element-citation></ref><ref id="CR3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bopp</surname><given-names>G</given-names></name><name><surname>Bender</surname><given-names>W</given-names></name><name><surname>Sch&#x000fc;tz</surname><given-names>CG</given-names></name></person-group><article-title>Validierung der Deutschen Version des Addiction Research Center Inventory (ARCI)</article-title><source>Suchtmedizin</source><year>2005</year><volume>7</volume><fpage>152</fpage><lpage>153</lpage></element-citation></ref><ref id="CR4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brun</surname><given-names>J</given-names></name><name><surname>Chamba</surname><given-names>G</given-names></name><name><surname>Khalfallah</surname><given-names>Y</given-names></name><name><surname>Girard</surname><given-names>P</given-names></name><name><surname>Boissy</surname><given-names>I</given-names></name><name><surname>Bastuji</surname><given-names>H</given-names></name><name><surname>Sassolas</surname><given-names>G</given-names></name><name><surname>Claustrat</surname><given-names>B</given-names></name></person-group><article-title>Effect of modafinil on plasma melatonin, cortisol and growth hormone rhythms, rectal temperature and performance in healthy subjects during a 36 h sleep deprivation</article-title><source>J Sleep Res</source><year>1998</year><volume>7</volume><fpage>105</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2869.1998.00100.x</pub-id><pub-id pub-id-type="pmid">9682182</pub-id></element-citation></ref><ref id="CR5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunt</surname><given-names>TM</given-names></name><name><surname>Koeter</surname><given-names>MW</given-names></name><name><surname>Niesink</surname><given-names>RJ</given-names></name><name><surname>van den Brink</surname><given-names>W</given-names></name></person-group><article-title>Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users</article-title><source>Psychopharmacology</source><year>2012</year><volume>220</volume><fpage>751</fpage><lpage>762</lpage><pub-id pub-id-type="doi">10.1007/s00213-011-2529-4</pub-id><pub-id pub-id-type="pmid">21993879</pub-id></element-citation></ref><ref id="CR6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de la Torre</surname><given-names>R</given-names></name><name><surname>Farre</surname><given-names>M</given-names></name><name><surname>Roset</surname><given-names>PN</given-names></name><name><surname>Lopez</surname><given-names>CH</given-names></name><name><surname>Mas</surname><given-names>M</given-names></name><name><surname>Ortuno</surname><given-names>J</given-names></name><name><surname>Menoyo</surname><given-names>E</given-names></name><name><surname>Pizarro</surname><given-names>N</given-names></name><name><surname>Segura</surname><given-names>J</given-names></name><name><surname>Cami</surname><given-names>J</given-names></name></person-group><article-title>Pharmacology of MDMA in humans</article-title><source>Ann N Y Acad Sci</source><year>2000</year><volume>914</volume><fpage>225</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2000.tb05199.x</pub-id><pub-id pub-id-type="pmid">11085324</pub-id></element-citation></ref><ref id="CR7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dittrich</surname><given-names>A</given-names></name></person-group><article-title>The standardized psychometric assessment of altered states of consciousness (ASCs) in humans</article-title><source>Pharmacopsychiatry</source><year>1998</year><volume>31</volume><issue>Suppl 2</issue><fpage>80</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1055/s-2007-979351</pub-id><pub-id pub-id-type="pmid">9754838</pub-id></element-citation></ref><ref id="CR8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumont</surname><given-names>GJ</given-names></name><name><surname>Verkes</surname><given-names>RJ</given-names></name></person-group><article-title>A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers</article-title><source>J Psychopharmacol</source><year>2006</year><volume>20</volume><fpage>176</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1177/0269881106063271</pub-id><pub-id pub-id-type="pmid">16510476</pub-id></element-citation></ref><ref id="CR9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumont</surname><given-names>GJ</given-names></name><name><surname>Sweep</surname><given-names>FC</given-names></name><name><surname>van der Steen</surname><given-names>R</given-names></name><name><surname>Hermsen</surname><given-names>R</given-names></name><name><surname>Donders</surname><given-names>AR</given-names></name><name><surname>Touw</surname><given-names>DJ</given-names></name><name><surname>van Gerven</surname><given-names>JM</given-names></name><name><surname>Buitelaar</surname><given-names>JK</given-names></name><name><surname>Verkes</surname><given-names>RJ</given-names></name></person-group><article-title>Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration</article-title><source>Soc Neurosci</source><year>2009</year><volume>4</volume><fpage>359</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1080/17470910802649470</pub-id><pub-id pub-id-type="pmid">19562632</pub-id></element-citation></ref><ref id="CR10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farre</surname><given-names>M</given-names></name><name><surname>de la Torre</surname><given-names>R</given-names></name><name><surname>Mathuna</surname><given-names>BO</given-names></name><name><surname>Roset</surname><given-names>PN</given-names></name><name><surname>Peiro</surname><given-names>AM</given-names></name><name><surname>Torrens</surname><given-names>M</given-names></name><name><surname>Ortuno</surname><given-names>J</given-names></name><name><surname>Pujadas</surname><given-names>M</given-names></name><name><surname>Cami</surname><given-names>J</given-names></name></person-group><article-title>Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics</article-title><source>Psychopharmacology</source><year>2004</year><volume>173</volume><fpage>364</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1007/s00213-004-1789-7</pub-id><pub-id pub-id-type="pmid">15071716</pub-id></element-citation></ref><ref id="CR11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forsling</surname><given-names>M</given-names></name><name><surname>Fallon</surname><given-names>JK</given-names></name><name><surname>Kicman</surname><given-names>AT</given-names></name><name><surname>Hutt</surname><given-names>AJ</given-names></name><name><surname>Cowan</surname><given-names>DA</given-names></name><name><surname>Henry</surname><given-names>JA</given-names></name></person-group><article-title>Arginine vasopressin release in response to the administration of 3,4-methylenedioxymethamphetamine (&#x0201c;ecstasy&#x0201d;): is metabolism a contributory factor?</article-title><source>J Pharm Pharmacol</source><year>2001</year><volume>53</volume><fpage>1357</fpage><lpage>1363</lpage><pub-id pub-id-type="doi">10.1211/0022357011777855</pub-id><pub-id pub-id-type="pmid">11697543</pub-id></element-citation></ref><ref id="CR12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Francis</surname><given-names>SM</given-names></name><name><surname>Kirkpatrick</surname><given-names>MG</given-names></name><name><surname>de Wit</surname><given-names>H</given-names></name><name><surname>Jacob</surname><given-names>S</given-names></name></person-group><article-title>Urinary and plasma oxytocin changes in response to MDMA or intranasal oxytocin administration</article-title><source>Psychoneuroendocrinology</source><year>2016</year><volume>74</volume><fpage>92</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.psyneuen.2016.08.011</pub-id><pub-id pub-id-type="pmid">27592327</pub-id></element-citation></ref><ref id="CR13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franke</surname><given-names>AG</given-names></name><name><surname>Gransmark</surname><given-names>P</given-names></name><name><surname>Agricola</surname><given-names>A</given-names></name><name><surname>Schuhle</surname><given-names>K</given-names></name><name><surname>Rommel</surname><given-names>T</given-names></name><name><surname>Sebastian</surname><given-names>A</given-names></name><name><surname>Ballo</surname><given-names>HE</given-names></name><name><surname>Gorbulev</surname><given-names>S</given-names></name><name><surname>Gerdes</surname><given-names>C</given-names></name><name><surname>Frank</surname><given-names>B</given-names></name><name><surname>Ruckes</surname><given-names>C</given-names></name><name><surname>Tuscher</surname><given-names>O</given-names></name><name><surname>Lieb</surname><given-names>K</given-names></name></person-group><article-title>Methylphenidate, modafinil, and caffeine for cognitive enhancement in chess: a double-blind, randomised controlled trial</article-title><source>Eur Neuropsychopharmacol</source><year>2017</year><volume>27</volume><fpage>248</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2017.01.006</pub-id><pub-id pub-id-type="pmid">28119083</pub-id></element-citation></ref><ref id="CR14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frohmader</surname><given-names>KS</given-names></name><name><surname>Pitchers</surname><given-names>KK</given-names></name><name><surname>Balfour</surname><given-names>ME</given-names></name><name><surname>Coolen</surname><given-names>LM</given-names></name></person-group><article-title>Mixing pleasures: review of the effects of drugs on sex behavior in humans and animal models</article-title><source>Horm Behav</source><year>2010</year><volume>58</volume><fpage>149</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1016/j.yhbeh.2009.11.009</pub-id><pub-id pub-id-type="pmid">20004662</pub-id></element-citation></ref><ref id="CR15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>DD</given-names></name><name><surname>Gu</surname><given-names>HH</given-names></name></person-group><article-title>Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs</article-title><source>BMC Pharmacol</source><year>2006</year><volume>6</volume><fpage>6</fpage><pub-id pub-id-type="doi">10.1186/1471-2210-6-6</pub-id><pub-id pub-id-type="pmid">16515684</pub-id></element-citation></ref><ref id="CR16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hannestad</surname><given-names>J</given-names></name><name><surname>Gallezot</surname><given-names>JD</given-names></name><name><surname>Planeta-Wilson</surname><given-names>B</given-names></name><name><surname>Lin</surname><given-names>SF</given-names></name><name><surname>Williams</surname><given-names>WA</given-names></name><name><surname>van Dyck</surname><given-names>CH</given-names></name><name><surname>Malison</surname><given-names>RT</given-names></name><name><surname>Carson</surname><given-names>RE</given-names></name><name><surname>Ding</surname><given-names>YS</given-names></name></person-group><article-title>Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo</article-title><source>Biol Psychiatry</source><year>2010</year><volume>68</volume><fpage>854</fpage><lpage>860</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2010.06.017</pub-id><pub-id pub-id-type="pmid">20691429</pub-id></element-citation></ref><ref id="CR17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>DS</given-names></name><name><surname>Baggott</surname><given-names>M</given-names></name><name><surname>Mendelson</surname><given-names>JH</given-names></name><name><surname>Mendelson</surname><given-names>JE</given-names></name><name><surname>Jones</surname><given-names>RT</given-names></name></person-group><article-title>Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans</article-title><source>Psychopharmacology</source><year>2002</year><volume>162</volume><fpage>396</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1007/s00213-002-1131-1</pub-id><pub-id pub-id-type="pmid">12172693</pub-id></element-citation></ref><ref id="CR18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henry</surname><given-names>JA</given-names></name><name><surname>Fallon</surname><given-names>JK</given-names></name><name><surname>Kicman</surname><given-names>AT</given-names></name><name><surname>Hutt</surname><given-names>AJ</given-names></name><name><surname>Cowan</surname><given-names>DA</given-names></name><name><surname>Forsling</surname><given-names>M</given-names></name></person-group><article-title>Low-dose MDMA (&#x0201c;ecstasy&#x0201d;) induces vasopressin secretion</article-title><source>Lancet</source><year>1998</year><volume>351</volume><fpage>1784</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)78744-4</pub-id><pub-id pub-id-type="pmid">9635954</pub-id></element-citation></ref><ref id="CR19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hysek</surname><given-names>CM</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Effects of MDMA alone and after pretreatement with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex</article-title><source>Psychopharmacology</source><year>2012</year><volume>224</volume><fpage>363</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1007/s00213-012-2761-6</pub-id><pub-id pub-id-type="pmid">22700038</pub-id></element-citation></ref><ref id="CR20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hysek</surname><given-names>CM</given-names></name><name><surname>Vollenweider</surname><given-names>FX</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Effects of a beta-blocker on the cardiovascular response to MDMA (ecstasy)</article-title><source>Emerg Med J</source><year>2010</year><volume>27</volume><fpage>586</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1136/emj.2009.079905</pub-id><pub-id pub-id-type="pmid">20378736</pub-id></element-citation></ref><ref id="CR21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hysek</surname><given-names>CM</given-names></name><name><surname>Simmler</surname><given-names>LD</given-names></name><name><surname>Ineichen</surname><given-names>M</given-names></name><name><surname>Grouzmann</surname><given-names>E</given-names></name><name><surname>Hoener</surname><given-names>MC</given-names></name><name><surname>Brenneisen</surname><given-names>R</given-names></name><name><surname>Huwyler</surname><given-names>J</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (&#x0201c;ecstasy&#x0201d;) in humans</article-title><source>Clin Pharmacol Ther</source><year>2011</year><volume>90</volume><fpage>246</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1038/clpt.2011.78</pub-id><pub-id pub-id-type="pmid">21677639</pub-id></element-citation></ref><ref id="CR22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hysek</surname><given-names>CM</given-names></name><name><surname>Brugger</surname><given-names>R</given-names></name><name><surname>Simmler</surname><given-names>LD</given-names></name><name><surname>Bruggisser</surname><given-names>M</given-names></name><name><surname>Donzelli</surname><given-names>M</given-names></name><name><surname>Grouzmann</surname><given-names>E</given-names></name><name><surname>Hoener</surname><given-names>MC</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Effects of the alpha<sub>2</sub>-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers</article-title><source>J Pharmacol Exp Ther</source><year>2012</year><volume>340</volume><fpage>286</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1124/jpet.111.188425</pub-id><pub-id pub-id-type="pmid">22034656</pub-id></element-citation></ref><ref id="CR23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hysek</surname><given-names>CM</given-names></name><name><surname>Domes</surname><given-names>G</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>MDMA enhances &#x0201c;mind reading&#x0201d; of positive emotions and impairs &#x0201c;mind reading&#x0201d; of negative emotions</article-title><source>Psychopharmacology</source><year>2012</year><volume>222</volume><fpage>293</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1007/s00213-012-2645-9</pub-id><pub-id pub-id-type="pmid">22277989</pub-id></element-citation></ref><ref id="CR24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hysek</surname><given-names>CM</given-names></name><name><surname>Simmler</surname><given-names>LD</given-names></name><name><surname>Nicola</surname><given-names>V</given-names></name><name><surname>Vischer</surname><given-names>N</given-names></name><name><surname>Donzelli</surname><given-names>M</given-names></name><name><surname>Kr&#x000e4;henb&#x000fc;hl</surname><given-names>S</given-names></name><name><surname>Grouzmann</surname><given-names>E</given-names></name><name><surname>Hoener</surname><given-names>MC</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Duloxetine inhibits effects of MDMA (&#x0201c;ecstasy&#x0201d;) in vitro and in humans in a randomized placebo-controlled laboratory study</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e36476</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0036476</pub-id><pub-id pub-id-type="pmid">22574166</pub-id></element-citation></ref><ref id="CR25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hysek</surname><given-names>CM</given-names></name><name><surname>Schmid</surname><given-names>Y</given-names></name><name><surname>Simmler</surname><given-names>LD</given-names></name><name><surname>Domes</surname><given-names>G</given-names></name><name><surname>Heinrichs</surname><given-names>M</given-names></name><name><surname>Eisenegger</surname><given-names>C</given-names></name><name><surname>Preller</surname><given-names>KH</given-names></name><name><surname>Quednow</surname><given-names>BB</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>MDMA enhances emotional empathy and prosocial behavior</article-title><source>Soc Cogn Affect Neurosci</source><year>2014</year><volume>9</volume><fpage>1645</fpage><lpage>1652</lpage><pub-id pub-id-type="doi">10.1093/scan/nst161</pub-id><pub-id pub-id-type="pmid">24097374</pub-id></element-citation></ref><ref id="CR26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hysek</surname><given-names>CM</given-names></name><name><surname>Simmler</surname><given-names>LD</given-names></name><name><surname>Schillinger</surname><given-names>N</given-names></name><name><surname>Meyer</surname><given-names>N</given-names></name><name><surname>Schmid</surname><given-names>Y</given-names></name><name><surname>Donzelli</surname><given-names>M</given-names></name><name><surname>Grouzmann</surname><given-names>E</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone and in combination</article-title><source>Int J Neuropsychopharmacol</source><year>2014</year><volume>17</volume><fpage>371</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1017/S1461145713001132</pub-id><pub-id pub-id-type="pmid">24103254</pub-id></element-citation></ref><ref id="CR27"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Janke</surname><given-names>W</given-names></name><name><surname>Debus</surname><given-names>G</given-names></name></person-group><source>Die Eigenschaftsw&#x000f6;rterliste</source><year>1978</year><publisher-loc>G&#x000f6;ttingen</publisher-loc><publisher-name>Hogrefe</publisher-name></element-citation></ref><ref id="CR28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jasinski</surname><given-names>DR</given-names></name></person-group><article-title>An evaluation of the abuse potential of modafinil using methylphenidate as a reference</article-title><source>J Psychopharmacol</source><year>2000</year><volume>14</volume><fpage>53</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1177/026988110001400107</pub-id><pub-id pub-id-type="pmid">10757254</pub-id></element-citation></ref><ref id="CR29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joyce</surname><given-names>PR</given-names></name><name><surname>Donald</surname><given-names>RA</given-names></name><name><surname>Nicholls</surname><given-names>MG</given-names></name><name><surname>Livesey</surname><given-names>JH</given-names></name><name><surname>Abbott</surname><given-names>RM</given-names></name></person-group><article-title>Endocrine and behavioral responses to methylphenidate in normal subjects</article-title><source>Biol Psychiatry</source><year>1986</year><volume>21</volume><fpage>1015</fpage><lpage>1023</lpage><pub-id pub-id-type="doi">10.1016/0006-3223(86)90282-9</pub-id><pub-id pub-id-type="pmid">3741917</pub-id></element-citation></ref><ref id="CR30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamilar-Britt</surname><given-names>P</given-names></name><name><surname>Bedi</surname><given-names>G</given-names></name></person-group><article-title>The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): controlled studies in humans and laboratory animals</article-title><source>Neurosci Biobehav Rev</source><year>2015</year><volume>57</volume><fpage>433</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2015.08.016</pub-id><pub-id pub-id-type="pmid">26408071</pub-id></element-citation></ref><ref id="CR31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirkpatrick</surname><given-names>MG</given-names></name><name><surname>Baggott</surname><given-names>MJ</given-names></name><name><surname>Mendelson</surname><given-names>JE</given-names></name><name><surname>Galloway</surname><given-names>GP</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name><name><surname>Hysek</surname><given-names>CM</given-names></name><name><surname>de Wit</surname><given-names>H</given-names></name></person-group><article-title>MDMA effects consistent across laboratories</article-title><source>Psychopharmacology</source><year>2014</year><volume>231</volume><fpage>3899</fpage><lpage>3905</lpage><pub-id pub-id-type="doi">10.1007/s00213-014-3528-z</pub-id><pub-id pub-id-type="pmid">24633447</pub-id></element-citation></ref><ref id="CR32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirkpatrick</surname><given-names>MG</given-names></name><name><surname>Lee</surname><given-names>R</given-names></name><name><surname>Wardle</surname><given-names>MC</given-names></name><name><surname>Jacob</surname><given-names>S</given-names></name><name><surname>de Wit</surname><given-names>H</given-names></name></person-group><article-title>Effects of MDMA and intranasal oxytocin on social and emotional processing</article-title><source>Neuropsychopharmacology</source><year>2014</year><volume>39</volume><fpage>1654</fpage><lpage>1663</lpage><pub-id pub-id-type="doi">10.1038/npp.2014.12</pub-id><pub-id pub-id-type="pmid">24448644</pub-id></element-citation></ref><ref id="CR33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirkpatrick</surname><given-names>M</given-names></name><name><surname>Delton</surname><given-names>AW</given-names></name><name><surname>Robertson</surname><given-names>TE</given-names></name><name><surname>de Wit</surname><given-names>H</given-names></name></person-group><article-title>Prosocial effects of MDMA: a measure of generosity</article-title><source>J Psychopharmacol</source><year>2015</year><volume>29</volume><fpage>661</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1177/0269881115573806</pub-id><pub-id pub-id-type="pmid">25735993</pub-id></element-citation></ref><ref id="CR34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korostenskaja</surname><given-names>M</given-names></name><name><surname>Kicic</surname><given-names>D</given-names></name><name><surname>Kahkonen</surname><given-names>S</given-names></name></person-group><article-title>The effect of methylphenidate on auditory information processing in healthy volunteers: a combined EEG/MEG study</article-title><source>Psychopharmacology</source><year>2008</year><volume>197</volume><fpage>475</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1007/s00213-007-1065-8</pub-id><pub-id pub-id-type="pmid">18264697</pub-id></element-citation></ref><ref id="CR35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuypers</surname><given-names>KPC</given-names></name><name><surname>Dolder</surname><given-names>PC</given-names></name><name><surname>Ramaekers</surname><given-names>JG</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Multifaceted empathy of healthy volunteers after single doses of MDMA: a pooled sample of placebo-controlled studies</article-title><source>J Psychopharmacol</source><year>2017</year><volume>31</volume><fpage>589</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1177/0269881117699617</pub-id><pub-id pub-id-type="pmid">28372480</pub-id></element-citation></ref><ref id="CR36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liakoni</surname><given-names>E</given-names></name><name><surname>Schaub</surname><given-names>MP</given-names></name><name><surname>Maier</surname><given-names>LJ</given-names></name><name><surname>Glauser</surname><given-names>GV</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>The use of prescription drugs, recreational drugs, and &#x0201c;soft enhancers&#x0201d; for cognitive enhancement among Swiss secondary school students</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><fpage>e0141289</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0141289</pub-id><pub-id pub-id-type="pmid">26505633</pub-id></element-citation></ref><ref id="CR37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liechti</surname><given-names>M</given-names></name></person-group><article-title>Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling</article-title><source>Swiss Med Wkly</source><year>2015</year><volume>145</volume><fpage>w14043</fpage><pub-id pub-id-type="pmid">25588018</pub-id></element-citation></ref><ref id="CR38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liechti</surname><given-names>ME</given-names></name><name><surname>Gamma</surname><given-names>A</given-names></name><name><surname>Vollenweider</surname><given-names>FX</given-names></name></person-group><article-title>Gender differences in the subjective effects of MDMA</article-title><source>Psychopharmacology</source><year>2001</year><volume>154</volume><fpage>161</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1007/s002130000648</pub-id><pub-id pub-id-type="pmid">11314678</pub-id></element-citation></ref><ref id="CR39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madras</surname><given-names>BK</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Jassen</surname><given-names>A</given-names></name><name><surname>Panas</surname><given-names>H</given-names></name><name><surname>Lynch</surname><given-names>L</given-names></name><name><surname>Johnson</surname><given-names>R</given-names></name><name><surname>Livni</surname><given-names>E</given-names></name><name><surname>Spencer</surname><given-names>TJ</given-names></name><name><surname>Bonab</surname><given-names>AA</given-names></name><name><surname>Miller</surname><given-names>GM</given-names></name><name><surname>Fischman</surname><given-names>AJ</given-names></name></person-group><article-title>Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro</article-title><source>J Pharmacol Exp Ther</source><year>2006</year><volume>319</volume><fpage>561</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1124/jpet.106.106583</pub-id><pub-id pub-id-type="pmid">16885432</pub-id></element-citation></ref><ref id="CR40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maier</surname><given-names>LJ</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name><name><surname>Herzig</surname><given-names>F</given-names></name><name><surname>Schaub</surname><given-names>MP</given-names></name></person-group><article-title>To dope or not to dope: neuroenhancement with prescription drugs and drugs of abuse among Swiss university students</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e77967</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0077967</pub-id><pub-id pub-id-type="pmid">24236008</pub-id></element-citation></ref><ref id="CR41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maier</surname><given-names>LJ</given-names></name><name><surname>Liakoni</surname><given-names>E</given-names></name><name><surname>Schildmann</surname><given-names>J</given-names></name><name><surname>Schaub</surname><given-names>MP</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Swiss university students&#x02019; attitudes toward pharmacological cognitive enhancement</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><fpage>e0144402</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0144402</pub-id><pub-id pub-id-type="pmid">26657300</pub-id></element-citation></ref><ref id="CR42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makris</surname><given-names>AP</given-names></name><name><surname>Rush</surname><given-names>CR</given-names></name><name><surname>Frederich</surname><given-names>RC</given-names></name><name><surname>Taylor</surname><given-names>AC</given-names></name><name><surname>Kelly</surname><given-names>TH</given-names></name></person-group><article-title>Behavioral and subjective effects of d-amphetamine and modafinil in healthy adults</article-title><source>Exp Clin Psychopharmacol</source><year>2007</year><volume>15</volume><fpage>123</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1037/1064-1297.15.2.123</pub-id><pub-id pub-id-type="pmid">17469936</pub-id></element-citation></ref><ref id="CR43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>WR</given-names></name><name><surname>Sloan</surname><given-names>JW</given-names></name><name><surname>Sapira</surname><given-names>JD</given-names></name><name><surname>Jasinski</surname><given-names>DR</given-names></name></person-group><article-title>Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man</article-title><source>Clin Pharmacol Ther</source><year>1971</year><volume>12</volume><fpage>245</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1002/cpt1971122part1245</pub-id><pub-id pub-id-type="pmid">5554941</pub-id></element-citation></ref><ref id="CR44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mas</surname><given-names>M</given-names></name><name><surname>Farre</surname><given-names>M</given-names></name><name><surname>de la Torre</surname><given-names>R</given-names></name><name><surname>Roset</surname><given-names>PN</given-names></name><name><surname>Ortuno</surname><given-names>J</given-names></name><name><surname>Segura</surname><given-names>J</given-names></name><name><surname>Cami</surname><given-names>J</given-names></name></person-group><article-title>Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans</article-title><source>J Pharmacol Exp Ther</source><year>1999</year><volume>290</volume><fpage>136</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">10381769</pub-id></element-citation></ref><ref id="CR45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McElrath</surname><given-names>K</given-names></name></person-group><article-title>MDMA and sexual behavior: ecstasy users&#x02019; perceptions about sexuality and sexual risk</article-title><source>Subst Use Misuse</source><year>2005</year><volume>40</volume><fpage>1461</fpage><lpage>1477</lpage><pub-id pub-id-type="doi">10.1081/JA-200066814</pub-id><pub-id pub-id-type="pmid">16048828</pub-id></element-citation></ref><ref id="CR46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mithoefer</surname><given-names>MC</given-names></name><name><surname>Wagner</surname><given-names>MT</given-names></name><name><surname>Mithoefer</surname><given-names>AT</given-names></name><name><surname>Jerome</surname><given-names>I</given-names></name><name><surname>Doblin</surname><given-names>R</given-names></name></person-group><article-title>The safety and efficacy of &#x000b1;3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study</article-title><source>J Psychopharmacol</source><year>2010</year><volume>25</volume><fpage>439</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1177/0269881110378371</pub-id><pub-id pub-id-type="pmid">20643699</pub-id></element-citation></ref><ref id="CR47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>U</given-names></name><name><surname>Rowe</surname><given-names>JB</given-names></name><name><surname>Rittman</surname><given-names>T</given-names></name><name><surname>Lewis</surname><given-names>C</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name><name><surname>Sahakian</surname><given-names>BJ</given-names></name></person-group><article-title>Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers</article-title><source>Neuropharmacology</source><year>2013</year><volume>64</volume><fpage>490</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2012.07.009</pub-id><pub-id pub-id-type="pmid">22820554</pub-id></element-citation></ref><ref id="CR48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>ID</given-names></name><name><surname>Maloumby</surname><given-names>R</given-names></name><name><surname>Beiderbeck</surname><given-names>DI</given-names></name><name><surname>Lukas</surname><given-names>M</given-names></name><name><surname>Landgraf</surname><given-names>R</given-names></name></person-group><article-title>Increased brain and plasma oxytocin after nasal and peripheral administration in rats and mice</article-title><source>Psychoneuroendocrinology</source><year>2013</year><volume>38</volume><fpage>1985</fpage><lpage>1993</lpage><pub-id pub-id-type="doi">10.1016/j.psyneuen.2013.03.003</pub-id><pub-id pub-id-type="pmid">23579082</pub-id></element-citation></ref><ref id="CR49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oehen</surname><given-names>P</given-names></name><name><surname>Traber</surname><given-names>R</given-names></name><name><surname>Widmer</surname><given-names>V</given-names></name><name><surname>Schnyder</surname><given-names>U</given-names></name></person-group><article-title>A randomized, controlled pilot study of MDMA (&#x000b1;3,4-methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD)</article-title><source>J Psychopharmacol</source><year>2013</year><volume>27</volume><fpage>40</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1177/0269881112464827</pub-id><pub-id pub-id-type="pmid">23118021</pub-id></element-citation></ref><ref id="CR50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parrott</surname><given-names>AC</given-names></name><name><surname>Gibbs</surname><given-names>A</given-names></name><name><surname>Scholey</surname><given-names>AB</given-names></name><name><surname>King</surname><given-names>R</given-names></name><name><surname>Owens</surname><given-names>K</given-names></name><name><surname>Swann</surname><given-names>P</given-names></name><name><surname>Ogden</surname><given-names>E</given-names></name><name><surname>Stough</surname><given-names>C</given-names></name></person-group><article-title>MDMA and methamphetamine: some paradoxical negative and positive mood changes in an acute dose laboratory study</article-title><source>Psychopharmacology</source><year>2011</year><volume>215</volume><fpage>527</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1007/s00213-011-2184-9</pub-id><pub-id pub-id-type="pmid">21318566</pub-id></element-citation></ref><ref id="CR51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passie</surname><given-names>T</given-names></name><name><surname>Hartmann</surname><given-names>U</given-names></name><name><surname>Schneider</surname><given-names>U</given-names></name><name><surname>Emrich</surname><given-names>HM</given-names></name><name><surname>Kruger</surname><given-names>TH</given-names></name></person-group><article-title>Ecstasy (MDMA) mimics the post-orgasmic state: impairment of sexual drive and function during acute MDMA-effects may be due to increased prolactin secretion</article-title><source>Med Hypotheses</source><year>2005</year><volume>64</volume><fpage>899</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1016/j.mehy.2004.11.044</pub-id><pub-id pub-id-type="pmid">15780482</pub-id></element-citation></ref><ref id="CR52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Persson</surname><given-names>TJ</given-names></name><name><surname>Ryder</surname><given-names>AG</given-names></name><name><surname>Pfaus</surname><given-names>JG</given-names></name></person-group><article-title>Comparing subjective ratings of sexual arousal and desire in partnered sexual activities from women of different sexual orientations</article-title><source>Arch Sex Behav</source><year>2016</year><volume>45</volume><fpage>1391</fpage><lpage>1402</lpage><pub-id pub-id-type="doi">10.1007/s10508-014-0468-y</pub-id><pub-id pub-id-type="pmid">25808718</pub-id></element-citation></ref><ref id="CR53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>WM</given-names></name><name><surname>Huang</surname><given-names>ZL</given-names></name><name><surname>Xu</surname><given-names>XH</given-names></name><name><surname>Matsumoto</surname><given-names>N</given-names></name><name><surname>Urade</surname><given-names>Y</given-names></name></person-group><article-title>Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil</article-title><source>J Neurosci</source><year>2008</year><volume>28</volume><fpage>8462</fpage><lpage>8469</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1819-08.2008</pub-id><pub-id pub-id-type="pmid">18716204</pub-id></element-citation></ref><ref id="CR54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Randall</surname><given-names>DC</given-names></name><name><surname>Shneerson</surname><given-names>JM</given-names></name><name><surname>Plaha</surname><given-names>KK</given-names></name><name><surname>File</surname><given-names>SE</given-names></name></person-group><article-title>Modafinil affects mood, but not cognitive function, in healthy young volunteers</article-title><source>Hum Psychopharmacol</source><year>2003</year><volume>18</volume><fpage>163</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1002/hup.456</pub-id><pub-id pub-id-type="pmid">12672167</pub-id></element-citation></ref><ref id="CR55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Randall</surname><given-names>DC</given-names></name><name><surname>Fleck</surname><given-names>NL</given-names></name><name><surname>Shneerson</surname><given-names>JM</given-names></name><name><surname>File</surname><given-names>SE</given-names></name></person-group><article-title>The cognitive-enhancing properties of modafinil are limited in non-sleep-deprived middle-aged volunteers</article-title><source>Pharmacol Biochem Behav</source><year>2004</year><volume>77</volume><fpage>547</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1016/j.pbb.2003.12.016</pub-id><pub-id pub-id-type="pmid">15006466</pub-id></element-citation></ref><ref id="CR56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rawson</surname><given-names>RA</given-names></name><name><surname>Washton</surname><given-names>A</given-names></name><name><surname>Domier</surname><given-names>CP</given-names></name><name><surname>Reiber</surname><given-names>C</given-names></name></person-group><article-title>Drugs and sexual effects: role of drug type and gender</article-title><source>J Subst Abus Treat</source><year>2002</year><volume>22</volume><fpage>103</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1016/S0740-5472(01)00215-X</pub-id></element-citation></ref><ref id="CR57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Repantis</surname><given-names>D</given-names></name><name><surname>Schlattmann</surname><given-names>P</given-names></name><name><surname>Laisney</surname><given-names>O</given-names></name><name><surname>Heuser</surname><given-names>I</given-names></name></person-group><article-title>Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review</article-title><source>Pharmacol Res</source><year>2010</year><volume>62</volume><fpage>187</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2010.04.002</pub-id><pub-id pub-id-type="pmid">20416377</pub-id></element-citation></ref><ref id="CR58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothman</surname><given-names>RB</given-names></name><name><surname>Baumann</surname><given-names>MH</given-names></name><name><surname>Dersch</surname><given-names>CM</given-names></name><name><surname>Romero</surname><given-names>DV</given-names></name><name><surname>Rice</surname><given-names>KC</given-names></name><name><surname>Carroll</surname><given-names>FI</given-names></name><name><surname>Partilla</surname><given-names>JS</given-names></name></person-group><article-title>Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin</article-title><source>Synapse</source><year>2001</year><volume>39</volume><fpage>32</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1002/1098-2396(20010101)39:1&#x0003c;32::AID-SYN5&#x0003e;3.0.CO;2-3</pub-id><pub-id pub-id-type="pmid">11071707</pub-id></element-citation></ref><ref id="CR59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowley</surname><given-names>HL</given-names></name><name><surname>Kulkarni</surname><given-names>RS</given-names></name><name><surname>Gosden</surname><given-names>J</given-names></name><name><surname>Brammer</surname><given-names>RJ</given-names></name><name><surname>Hackett</surname><given-names>D</given-names></name><name><surname>Heal</surname><given-names>DJ</given-names></name></person-group><article-title>Differences in the neurochemical and behavioural profiles of lisdexamfetamine methylphenidate and modafinil revealed by simultaneous dual-probe microdialysis and locomotor activity measurements in freely-moving rats</article-title><source>J Psychopharmacol</source><year>2014</year><volume>28</volume><fpage>254</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1177/0269881113513850</pub-id><pub-id pub-id-type="pmid">24327450</pub-id></element-citation></ref><ref id="CR60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rush</surname><given-names>CR</given-names></name><name><surname>Kelly</surname><given-names>TH</given-names></name><name><surname>Hays</surname><given-names>LR</given-names></name><name><surname>Baker</surname><given-names>RW</given-names></name><name><surname>Wooten</surname><given-names>AF</given-names></name></person-group><article-title>Acute behavioral and physiological effects of modafinil in drug abusers</article-title><source>Behav Pharmacol</source><year>2002</year><volume>13</volume><fpage>105</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1097/00008877-200203000-00002</pub-id><pub-id pub-id-type="pmid">11981223</pub-id></element-citation></ref><ref id="CR61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmeichel</surname><given-names>BE</given-names></name><name><surname>Berridge</surname><given-names>CW</given-names></name></person-group><article-title>Neurocircuitry underlying the preferential sensitivity of prefrontal catecholamines to low-dose psychostimulants</article-title><source>Neuropsychopharmacology</source><year>2013</year><volume>38</volume><fpage>1079</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.1038/npp.2013.6</pub-id></element-citation></ref><ref id="CR62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmid</surname><given-names>Y</given-names></name><name><surname>Hysek</surname><given-names>CM</given-names></name><name><surname>Simmler</surname><given-names>LD</given-names></name><name><surname>Crockett</surname><given-names>MJ</given-names></name><name><surname>Quednow</surname><given-names>BB</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Differential effects of MDMA and methylphenidate on social cognition</article-title><source>J Psychopharmacol</source><year>2014</year><volume>28</volume><fpage>847</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1177/0269881114542454</pub-id><pub-id pub-id-type="pmid">25052243</pub-id></element-citation></ref><ref id="CR63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmid</surname><given-names>Y</given-names></name><name><surname>Enzler</surname><given-names>F</given-names></name><name><surname>Gasser</surname><given-names>P</given-names></name><name><surname>Grouzmann</surname><given-names>E</given-names></name><name><surname>Preller</surname><given-names>KH</given-names></name><name><surname>Vollenweider</surname><given-names>FX</given-names></name><name><surname>Brenneisen</surname><given-names>R</given-names></name><name><surname>Muller</surname><given-names>F</given-names></name><name><surname>Borgwardt</surname><given-names>S</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Acute effects of lysergic acid diethylamide in healthy subjects</article-title><source>Biol Psychiatry</source><year>2015</year><volume>78</volume><fpage>544</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2014.11.015</pub-id><pub-id pub-id-type="pmid">25575620</pub-id></element-citation></ref><ref id="CR64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmid</surname><given-names>Y</given-names></name><name><surname>Hysek</surname><given-names>CM</given-names></name><name><surname>Preller</surname><given-names>KH</given-names></name><name><surname>Bosch</surname><given-names>OG</given-names></name><name><surname>Bilderbeck</surname><given-names>AC</given-names></name><name><surname>Rogers</surname><given-names>RD</given-names></name><name><surname>Quednow</surname><given-names>BB</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Effects of methylphenidate and MDMA on appraisal of erotic stimuli and intimate relationships</article-title><source>Eur Neuropsychopharmacol</source><year>2015</year><volume>25</volume><fpage>17</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2014.11.020</pub-id><pub-id pub-id-type="pmid">25498417</pub-id></element-citation></ref><ref id="CR65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scoriels</surname><given-names>L</given-names></name><name><surname>Barnett</surname><given-names>JH</given-names></name><name><surname>Murray</surname><given-names>GK</given-names></name><name><surname>Cherukuru</surname><given-names>S</given-names></name><name><surname>Fielding</surname><given-names>M</given-names></name><name><surname>Cheng</surname><given-names>F</given-names></name><name><surname>Lennox</surname><given-names>BR</given-names></name><name><surname>Sahakian</surname><given-names>BJ</given-names></name><name><surname>Jones</surname><given-names>PB</given-names></name></person-group><article-title>Effects of modafinil on emotional processing in first episode psychosis</article-title><source>Biol Psychiatry</source><year>2011</year><volume>69</volume><fpage>457</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2010.09.043</pub-id><pub-id pub-id-type="pmid">21109234</pub-id></element-citation></ref><ref id="CR66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seibert</surname><given-names>J</given-names></name><name><surname>Hysek</surname><given-names>CM</given-names></name><name><surname>Penno</surname><given-names>CA</given-names></name><name><surname>Schmid</surname><given-names>Y</given-names></name><name><surname>Kratschmar</surname><given-names>DV</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name><name><surname>Odermatt</surname><given-names>A</given-names></name></person-group><article-title>Acute effects of 3,4-methylenedioxymethamphetamine and methylphenidate on circulating steroid levels in healthy subjects</article-title><source>Neuroendocrinology</source><year>2014</year><volume>100</volume><fpage>17</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1159/000364879</pub-id><pub-id pub-id-type="pmid">24903002</pub-id></element-citation></ref><ref id="CR67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seifritz</surname><given-names>E</given-names></name><name><surname>Baumann</surname><given-names>P</given-names></name><name><surname>Muller</surname><given-names>MJ</given-names></name><name><surname>Annen</surname><given-names>O</given-names></name><name><surname>Amey</surname><given-names>M</given-names></name><name><surname>Hemmeter</surname><given-names>U</given-names></name><name><surname>Hatzinger</surname><given-names>M</given-names></name><name><surname>Chardon</surname><given-names>F</given-names></name><name><surname>Holsboer-Trachsler</surname><given-names>E</given-names></name></person-group><article-title>Neuroendocrine effects of a 20-mg citalopram infusion in healthy males: a placebo-controlled evaluation of citalopram as 5-HT function probe</article-title><source>Neuropsychopharmacology</source><year>1996</year><volume>14</volume><fpage>253</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1016/0893-133X(95)00117-V</pub-id><pub-id pub-id-type="pmid">8924193</pub-id></element-citation></ref><ref id="CR68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semple</surname><given-names>SJ</given-names></name><name><surname>Patterson</surname><given-names>TL</given-names></name><name><surname>Grant</surname><given-names>I</given-names></name></person-group><article-title>Motivations associated with methamphetamine use among HIV+ men who have sex with men</article-title><source>J Subst Abus Treat</source><year>2002</year><volume>22</volume><fpage>149</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/S0740-5472(02)00223-4</pub-id></element-citation></ref><ref id="CR69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simmler</surname><given-names>LD</given-names></name><name><surname>Hysek</surname><given-names>CM</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Sex differences in the effects of MDMA (ecstasy) on plasma copeptin in healthy subjects</article-title><source>J Clin Endocrinol Metab</source><year>2011</year><volume>96</volume><fpage>2844</fpage><lpage>2850</lpage><pub-id pub-id-type="doi">10.1210/jc.2011-1143</pub-id><pub-id pub-id-type="pmid">21715530</pub-id></element-citation></ref><ref id="CR70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simmler</surname><given-names>L</given-names></name><name><surname>Buser</surname><given-names>T</given-names></name><name><surname>Donzelli</surname><given-names>M</given-names></name><name><surname>Schramm</surname><given-names>Y</given-names></name><name><surname>Dieu</surname><given-names>LH</given-names></name><name><surname>Huwyler</surname><given-names>J</given-names></name><name><surname>Chaboz</surname><given-names>S</given-names></name><name><surname>Hoener</surname><given-names>M</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Pharmacological characterization of designer cathinones in vitro</article-title><source>Br J Pharmacol</source><year>2013</year><volume>168</volume><fpage>458</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2012.02145.x</pub-id><pub-id pub-id-type="pmid">22897747</pub-id></element-citation></ref><ref id="CR71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simmler</surname><given-names>LD</given-names></name><name><surname>Rickli</surname><given-names>A</given-names></name><name><surname>Schramm</surname><given-names>Y</given-names></name><name><surname>Hoener</surname><given-names>MC</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives</article-title><source>Biochem Pharmacol</source><year>2014</year><volume>88</volume><fpage>237</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2014.01.024</pub-id><pub-id pub-id-type="pmid">24486525</pub-id></element-citation></ref><ref id="CR72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sommers</surname><given-names>DK</given-names></name><name><surname>van Wyk</surname><given-names>M</given-names></name><name><surname>Snyman</surname><given-names>JR</given-names></name></person-group><article-title>Dexfenfluramine-induced prolactin release as an index of central synaptosomal 5-hydroxytryptamine during treatment with fluoxetine</article-title><source>Eur J Clin Pharmacol</source><year>1994</year><volume>46</volume><fpage>441</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1007/BF00191908</pub-id><pub-id pub-id-type="pmid">7957540</pub-id></element-citation></ref><ref id="CR73"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Spielberger</surname><given-names>CD</given-names></name><name><surname>Gorsuch</surname><given-names>RC</given-names></name><name><surname>Lusheme</surname><given-names>RE</given-names></name></person-group><source>Manual for the Stait Trait Anxiety Inventory</source><year>1970</year><publisher-loc>Palo Alto</publisher-loc><publisher-name>Consulting Psychologists Press</publisher-name></element-citation></ref><ref id="CR74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strajhar</surname><given-names>P</given-names></name><name><surname>Schmid</surname><given-names>Y</given-names></name><name><surname>Liakoni</surname><given-names>E</given-names></name><name><surname>Dolder</surname><given-names>PC</given-names></name><name><surname>Rentsch</surname><given-names>KM</given-names></name><name><surname>Kratschmar</surname><given-names>DV</given-names></name><name><surname>Odermatt</surname><given-names>A</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Acute effects of lysergic acid diethylamide on circulating steroid levels in healthy subjects</article-title><source>J Neuroendocrinol</source><year>2016</year><volume>28</volume><fpage>12374</fpage><pub-id pub-id-type="doi">10.1111/jne.12374</pub-id><pub-id pub-id-type="pmid">26849997</pub-id></element-citation></ref><ref id="CR75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Studerus</surname><given-names>E</given-names></name><name><surname>Gamma</surname><given-names>A</given-names></name><name><surname>Vollenweider</surname><given-names>FX</given-names></name></person-group><article-title>Psychometric evaluation of the altered states of consciousness rating scale (OAV)</article-title><source>PLoS One</source><year>2010</year><volume>5</volume><fpage>e12412</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0012412</pub-id><pub-id pub-id-type="pmid">20824211</pub-id></element-citation></ref><ref id="CR76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tancer</surname><given-names>M</given-names></name><name><surname>Johanson</surname><given-names>CE</given-names></name></person-group><article-title>Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP</article-title><source>Drug Alcohol Depend</source><year>2003</year><volume>72</volume><fpage>33</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/S0376-8716(03)00172-8</pub-id><pub-id pub-id-type="pmid">14563541</pub-id></element-citation></ref><ref id="CR77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theall</surname><given-names>KP</given-names></name><name><surname>Elifson</surname><given-names>KW</given-names></name><name><surname>Sterk</surname><given-names>CE</given-names></name></person-group><article-title>Sex, touch, and HIV risk among ecstasy users</article-title><source>AIDS Behav</source><year>2006</year><volume>10</volume><fpage>169</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1007/s10461-005-9059-1</pub-id><pub-id pub-id-type="pmid">16456728</pub-id></element-citation></ref><ref id="CR78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>MR</given-names></name><name><surname>Callaghan</surname><given-names>PD</given-names></name><name><surname>Hunt</surname><given-names>GE</given-names></name><name><surname>Cornish</surname><given-names>JL</given-names></name><name><surname>McGregor</surname><given-names>IS</given-names></name></person-group><article-title>A role for oxytocin and 5-HT<sub>1A</sub> receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine (&#x0201c;ecstasy&#x0201d;)</article-title><source>Neuroscience</source><year>2007</year><volume>146</volume><fpage>509</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2007.02.032</pub-id><pub-id pub-id-type="pmid">17383105</pub-id></element-citation></ref><ref id="CR79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toledano</surname><given-names>R</given-names></name><name><surname>Pfaus</surname><given-names>J</given-names></name></person-group><article-title>The Sexual Arousal and Desire Inventory (SADI): a multidimensional scale to assess subjective sexual arousal and desire</article-title><source>J Sex Med</source><year>2006</year><volume>3</volume><fpage>853</fpage><lpage>877</lpage><pub-id pub-id-type="doi">10.1111/j.1743-6109.2006.00293.x</pub-id><pub-id pub-id-type="pmid">16942530</pub-id></element-citation></ref><ref id="CR80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>DC</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name><name><surname>Clark</surname><given-names>L</given-names></name><name><surname>Aron</surname><given-names>AR</given-names></name><name><surname>Dowson</surname><given-names>J</given-names></name><name><surname>Sahakian</surname><given-names>BJ</given-names></name></person-group><article-title>Cognitive enhancing effects of modafinil in healthy volunteers</article-title><source>Psychopharmacology</source><year>2003</year><volume>165</volume><fpage>260</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1007/s00213-002-1250-8</pub-id><pub-id pub-id-type="pmid">12417966</pub-id></element-citation></ref><ref id="CR81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>DC</given-names></name><name><surname>Clark</surname><given-names>L</given-names></name><name><surname>Dowson</surname><given-names>J</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name><name><surname>Sahakian</surname><given-names>BJ</given-names></name></person-group><article-title>Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder</article-title><source>Biol Psychiatry</source><year>2004</year><volume>55</volume><fpage>1031</fpage><lpage>1040</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2004.02.008</pub-id><pub-id pub-id-type="pmid">15121488</pub-id></element-citation></ref><ref id="CR82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vizeli</surname><given-names>P</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Safety pharmacology of acute MDMA administration in healthy subjects</article-title><source>J Psychopharmacol</source><year>2017</year><volume>31</volume><fpage>576</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1177/0269881117691569</pub-id><pub-id pub-id-type="pmid">28443695</pub-id></element-citation></ref><ref id="CR83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volkow</surname><given-names>ND</given-names></name><name><surname>Wang</surname><given-names>GJ</given-names></name><name><surname>Fowler</surname><given-names>JS</given-names></name><name><surname>Telang</surname><given-names>F</given-names></name><name><surname>Jayne</surname><given-names>M</given-names></name><name><surname>Wong</surname><given-names>C</given-names></name></person-group><article-title>Stimulant-induced enhanced sexual desire as a potential contributing factor in HIV transmission</article-title><source>Am J Psychiatry</source><year>2007</year><volume>164</volume><fpage>157</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1176/ajp.2007.164.1.157</pub-id><pub-id pub-id-type="pmid">17202559</pub-id></element-citation></ref><ref id="CR84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vollenweider</surname><given-names>FX</given-names></name><name><surname>Gamma</surname><given-names>A</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name><name><surname>Huber</surname><given-names>T</given-names></name></person-group><article-title>Psychological and cardiovascular effects and short-term sequelae of MDMA (&#x0201c;ecstasy&#x0201d;) in MDMA-naive healthy volunteers</article-title><source>Neuropsychopharmacology</source><year>1998</year><volume>19</volume><fpage>241</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1038/sj.npp.1395197</pub-id><pub-id pub-id-type="pmid">9718588</pub-id></element-citation></ref><ref id="CR85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>SR</given-names></name><name><surname>Obradovic</surname><given-names>T</given-names></name><name><surname>Imel</surname><given-names>KM</given-names></name><name><surname>Wheaton</surname><given-names>MJ</given-names></name></person-group><article-title>The effects of methylenedioxymethamphetamine (MDMA, &#x0201c;ecstasy&#x0201d;) on monoaminergic neurotransmission in the central nervous system</article-title><source>Prog Neurobiol</source><year>1996</year><volume>49</volume><fpage>455</fpage><lpage>479</lpage><pub-id pub-id-type="doi">10.1016/0301-0082(96)00027-5</pub-id><pub-id pub-id-type="pmid">8895996</pub-id></element-citation></ref><ref id="CR86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>TL</given-names></name><name><surname>Justice</surname><given-names>AJ</given-names></name><name><surname>de Wit</surname><given-names>H</given-names></name></person-group><article-title>Differential subjective effects of D-amphetamine by gender, hormone levels and menstrual cycle phase</article-title><source>Pharmacol Biochem Behav</source><year>2002</year><volume>73</volume><fpage>729</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1016/S0091-3057(02)00818-3</pub-id><pub-id pub-id-type="pmid">12213517</pub-id></element-citation></ref><ref id="CR87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>YN</given-names></name><name><surname>King</surname><given-names>SP</given-names></name><name><surname>Laughton</surname><given-names>WB</given-names></name><name><surname>McCormick</surname><given-names>GC</given-names></name><name><surname>Grebow</surname><given-names>PE</given-names></name></person-group><article-title>Single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers</article-title><source>J Clin Pharmacol</source><year>1998</year><volume>38</volume><fpage>276</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1002/j.1552-4604.1998.tb04425.x</pub-id><pub-id pub-id-type="pmid">9549666</pub-id></element-citation></ref><ref id="CR88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>YN</given-names></name><name><surname>Simcoe</surname><given-names>D</given-names></name><name><surname>Hartman</surname><given-names>LN</given-names></name><name><surname>Laughton</surname><given-names>WB</given-names></name><name><surname>King</surname><given-names>SP</given-names></name><name><surname>McCormick</surname><given-names>GC</given-names></name><name><surname>Grebow</surname><given-names>PE</given-names></name></person-group><article-title>A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers</article-title><source>J Clin Pharmacol</source><year>1999</year><volume>39</volume><fpage>30</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1177/00912709922007534</pub-id><pub-id pub-id-type="pmid">9987698</pub-id></element-citation></ref><ref id="CR89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zemishlany</surname><given-names>Z</given-names></name><name><surname>Aizenberg</surname><given-names>D</given-names></name><name><surname>Weizman</surname><given-names>A</given-names></name></person-group><article-title>Subjective effects of MDMA (&#x02018;ecstasy&#x02019;) on human sexual function</article-title><source>Eur Psychiatry</source><year>2001</year><volume>16</volume><fpage>127</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1016/S0924-9338(01)00550-8</pub-id><pub-id pub-id-type="pmid">11311178</pub-id></element-citation></ref><ref id="CR90"><mixed-citation publication-type="other">Zerssen DV (1976) Die Beschwerden-Liste. M&#x000fc;nchener Informationssystem. Psychis, M&#x000fc;nchen</mixed-citation></ref><ref id="CR91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zolkowska</surname><given-names>D</given-names></name><name><surname>Jain</surname><given-names>R</given-names></name><name><surname>Rothman</surname><given-names>RB</given-names></name><name><surname>Partilla</surname><given-names>JS</given-names></name><name><surname>Roth</surname><given-names>BL</given-names></name><name><surname>Setola</surname><given-names>V</given-names></name><name><surname>Prisinzano</surname><given-names>TE</given-names></name><name><surname>Baumann</surname><given-names>MH</given-names></name></person-group><article-title>Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil</article-title><source>J Pharmacol Exp Ther</source><year>2009</year><volume>329</volume><fpage>738</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1124/jpet.108.146142</pub-id><pub-id pub-id-type="pmid">19197004</pub-id></element-citation></ref></ref-list></back></article>